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The Hepatitis B virus (HBV) is a non-cytopathic hepatotropic DNA virus, 
with a host range limited to humans and chimpanzees.  Despite the availability 
of a prophylactic vaccine, approximately 350 million individuals are chronically 
infected worldwide and it is one of the leading causes of hepatocellular 
carcinoma (HCC).  Depletion of T cells in experimentally infected chimpanzees 
and the longitudinal analysis of T cell responses in both acute and chronic 
patients have shown the crucial importance of T cells in the control and 
clearance of HBV infection.  This thesis will focus on two aspects of T cell 
responses during HBV infection, namely: 1) the factors that influence the 
immunodominant hierarchy of HBV-specific T cells and 2) immunoprotection of 
HBV-specific T cells during hepatic flares (HF). 
 
Chapter 1 – Immunodominance of HBV-specific T cells 
Repertoire composition, quantity and qualitative functional ability are the 
parameters that define virus specific T cell responses and are linked with their 
potential to control infection.  By taking advantage of the segregation of 
different HBV genotypes in geographically and genetically distinct host 
populations, we were able to directly analyze the impact that host and virus 
variables exert on these virus-specific T cells parameters.  T cell responses 
against the entire HBV proteome was analyzed in a total of 109 HBV infected 
Chinese or Caucasian subjects.  We demonstrate that HBV-specific T cell 
quantity is determined by the virological and clinical profile of the patients, 
which outweighs any influence of race or viral diversity.  In contrast, HBV-
specific T cell repertoire is divergent in the two ethnic groups with T cell 
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epitopes frequently found in Caucasian patients seldom detected in Chinese 
patients, demonstrating the ability of HLA micro-polymorphisms to diversify 
the T cell response.  In conclusion, we provide a direct biological evaluation of 
the impact that host and virus variables exert on the immunodominance of virus-
specific T cell response.   
 
Chapter 2 – Immunoprotection of HBV-specific T cells during hepatic flares 
The pathogenesis of HF in patients chronically infected with HBV is 
controversial.  Since HBV is not a directly cytopathic virus, an increase in virus-
specific T cell response has been conventionally thought to occur during HF, 
even though experimental evidence to support such a scenario is scarce.  
Therefore, we studied the kinetics of innate and adaptive immune activation 
during HF in chronic hepatitis B to answer the following questions of 
immunoprotection: a) Is the HBV replication rebound that precedes HF 
associated with activation of innate or adaptive immunological events?; b) Are 
HF associated with the recovery of HBV-specific immunity?  We analyzed 
longitudinally soluble (IFN-α, IL-1β, TNF-α, IL-6, IL-8, IL-10, CCL-2, CCL-3, 
CXCL-9, CXCL-10) and cellular (HBV-specific T, NK and T-regulatory cells) 
immunological parameters in patients (n=5) who developed HF after anti-viral 
therapy withdrawal, and cross-sectionally in chronic (n=29) and acute hepatitis 
B patients (n=5).  A progressive increase of HBV replication precedes HF but 
occurs without detection of innate immune activation, with the exception of 
increased serum CXCL-8.  Despite the absence of increased circulatory HBV-
specific T or activated NK cells, HF were temporally associated with high serum 
levels of IFN-γ inducible chemokines CXCL-9 and CXCL-10 (but not CCL-2 or 
  
vii
CCL-3).  CXCL-9 and CXCL-10 also displayed different in vitro 
requirements for activation and are differentially produced in liver injury 
present in acute or chronic patients.  In conclusion, we demonstrate that both 
HBV replication rebound and HF were not associated with a recovery of 
peripheral HBV-specific T cell immunity and confirm that CXCL-9 and CXCL-
10 are major mediators of liver inflammation.  Their differential expression in 
acute versus chronic patients also suggests the presence of different mechanisms 
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The Hepatitis B virus (HBV), a member of the Hepadnaviridae virus family, is a 
non-cytopathic hepatotropic DNA virus, with a host range limited to humans 
and chimpanzees, a worldwide distribution, and an ability to cause liver diseases 
with varying severity in different individuals 1, 2.  Even with the availability of 
an effective prophylactic recombinant vaccine, it is estimated that two billion of 
the global population have been infected with the virus before and that the 
worldwide HBV related deaths amount to 500 000 – 700 000 each year  3.   
 
Among the HBV infected subjects, some were able to control the infection and 
clear the virus from the bloodstream without any clinically evident symptoms 
(sub-clinical infection) or with an acute inflammation of the liver (acute 
hepatitis) that resolves without persistent secondary clinical complications 2.  
However, some patients are unable to clear the virus and develop chronic 
infection, defined as subjects positive for hepatitis B surface antigen (HBsAg) 
for more than six months 4, 5.  An estimated 350 million individuals are 
chronically infected with HBV worldwide, with a high incidence occurring 
particularly in Asia 6.  Most chronic HBV subjects remain largely asymptomatic 
without the development of severe liver diseases, but approximately 15-40% of 
HBV carriers progress to develop fibrosis, cirrhosis, liver failure and 
hepatocellular carcinoma (HCC) 7.  Furthermore, greater than 50% of primary 





Hepatitis B Virus (HBV) 
The HBV genome is circular and partially double stranded consisting of 
approximately 3200 nucleotides contained in an icosahedral capsid that is 
enveloped by a lipid bilayer 9, 10.  The genome contains four overlapping open 
reading frames that codes for seven polypeptides; the structural nucleocapsid or 
core protein (containing the core antigen, HBcAg) and the three variants of the 
surface envelope proteins (containing the surface antigen, HBsAg) with the pre-
S2 section, with both pre-S1 and pre-S2 sections or without both sections, the 
non-structural viral polymerase, the secretory form of the pre-core protein 
(containing the antigen, HBeAg) and the X protein 9, 10.   
 
The core and envelope proteins have a structural function, where it is involved 
in the encapsidation of the viral RNA/DNA, and the coating of the entire virus 
particle upon budding respectively 9, 10.  The function of the secreted pre-core 
protein is unknown but it may have a role in the suppression of the HBV 
specific immune response.  The X protein is a transactivator of both viral and 
cellular genes, and is believed to be involved in the development of HCC in 
chronically infected individuals though it is yet to be conclusive 10, 11.  In 
addition to the DNA polymerase activity, HBV polymerase also has a reverse 
transcriptase activity and an RNAse H activity that removes the RNA 
component of a DNA/RNA duplex, but it lacks proofreading capabilities 11.   
 
HBV Genotypes 
The lack of proofreading capacity of the HBV polymerase has resulted in 




population at any given time can be perceived to be composed of various 
mutants 12, 13  It is this extensive variation that demands HBV to be classified 
into eight genotypes (A-H) based on an intergroup divergence of more than 8% 
in the complete genome sequence and 4% in the HBV surface protein gene 14.  
Subtypes have also been described in genotypes A, B, C and F 14.   
 
Interestingly, the different HBV genotypes have a distinct geographical 
distribution (Figure 1.).  Genotypes B and C are characteristically found in Asia 
with genotype B infecting majority of South-East Asian individuals, while 
genotype A and D are more commonly associated with HBV infections in 
Europe and North America 8, 14.  Furthermore, literature has suggested the 
possibility of the different genotypes to influence disease severity, likelihood of 
complications and response to treatment of chronic HBV infections 15, 16.  
Studies comparing HBV genotype B and C showed that genotype B is 
associated with earlier spontaneous HBeAg seroconversion with or without 
pegylated IFN (Peg-IFN) treatment, slower progression to cirrhosis as well as a 
less frequent and slower development of HCC than genotype C 17-19.  However, 
findings from HBV genotype comparison studies are often conflicting, hence a 
definitive role of HBV genotypes in HBV infection has yet to be established 15.   
 
HBV-specific Immune Response 
The general immunological progression pattern following HBV infection 
consists of three distinct stages: an early latent phase where viral replication and 
host immune response against HBV is undetectable, a rapid viral replication 




that differs between acute and chronic patients (Figure 2.) 20.  Patients that 
proceed to resolve the infection have a robust HBV specific adaptive immune 
response as opposed to patients who develop chronicity where such adaptive 
immune response is weak or absent (Figure 2.) 20.  Various critical events in 
each of the different phases are believed to affect the eventual outcome of the 
infection and determine if chronicity develops. 
 
Latent Phase 
Unique to HBV, the virus does not replicate efficiently immediately after 
infection, instead it requires 4-7 weeks of incubation period before HBV-DNA 
and antigens reach a detectable level in the serum 21.  Detailed longitudinal 
analyses of global gene expression in infected chimpanzees revealed that 
antiviral cytokine genes like interferon (IFN) α and β are either weakly or not 
triggered during the latent phase 22.  Therefore, it seems that the initial latent 
phase is unlikely attributed to an immune mediated inhibition of HBV 
replication, but more of an escape mechanism utilized by the virus.  One 
possible explanation for the absence of IFN α and β genes activation has been 
suggested to be the consequence of the viral life cycle where the viral genetic 
material is encapsidated, preventing host cellular recognition 22.  Furthermore, 
there is accumulating evidence to suggest that HBV might even interfere with 
the expression of Toll-like receptors (TLRs), in particular, reduced expression of 
TLR-2 has been observed in hepatocytes, Kupffer cells and monocytes of 
HBeAg positive chronic patients and in HBeAg-expressing HepG2 lines 23.  
However, such early events in the natural infection of HBV are hard to analyse 




phase when clinical symptoms emerge, thus the impact of this latent period on 
the course and outcome of HBV infection remains largely unknown. 
 
Viral Replication Phase 
The phase immediately after the rapid expansion of HBV is an important link 
between the innate immunity and the activation of adaptive immunity against 
HBV.  The same study by Wieland et al. (2004) showed that chimpanzees with a 
typical acute HBV infection profile had a robust induction of T helper type 1 
(Th1) genes including IFN-γ, tumour necrosis factor α (TNF-α) and RANTES 
immediately after the latent phase.  However, experimentally infected 
woodchucks that develop chronicity seem to lack the initial large production of 
Th1 cytokines 24, 25.  In line with observations in the woodchuck model of HBV 
infection, the development of chronicity is clinically associated with the absence 
or mild symptoms of hepatitis, while patients who resolve the infection often 
experience acute hepatitis 20.  This led to the suggestion that the ability of the 
innate immunity to produce large amounts of IFN-γ or Th1 cytokines might 
influence the activation of the adaptive immunity and determine the eventual 
likelihood of developing chronicity 20.  Even though the mechanisms of innate 
immunity activation during HBV infection is still unclear, immunological events 
occurring during the initial phases of infection seems to have a profound effect 
on the eventual development of the adaptive immune response and the outcome 





Adaptive Immunity Phase 
The important role of the adaptive immunity in determining the outcome of a 
HBV infection has been demonstrated through various studies, both in 
experimentally infected chimpanzees and in patients 21, 26-34.  This antiviral 
ability requires both the humoral and cellular arm of the adaptive immune 
system as well as a complex interplay between the different components 35.   
 
The humoral arm typically provides protection through the production of 
neutralizing antibodies against viral particles, preventing infection in a similar 
fashion to HBV vaccination.  In particular, HBV clearance has been associated 
with the production of anti-HBs antibodies 36, and sera with high levels of anti-
HBs antibodies have been shown to be able to control HBV infection 37.  Even 
though the humoral immune response does play a role in the control of HBV, 
this branch of the adaptive immunity seems comparatively unexplored in the 
context of HBV infection.  On the other hand, T cell responses have been widely 
studied in HBV.  Depletion of CD8 or CD4 T cells in chimpanzees that have 
been experimentally infected with a HBV innoculum size that typically causes 
an acute infection, results in a prolonged and persistent infection 21, 26.  
Clinically, the expansion of HBV-specific CD8 and CD4 T-cells has also been 
observed to precede viral clearance and was present only in patients who 
controlled the infection 21, 32.  Furthermore, the longitudinal analysis of a HBV 
and HCV co-infected individual who developed chronic HBV infection shows 
the presence of multi-specific CD8 T-cells with the absence of CD4 T-cells 38.  
This suggests that the absence of CD4 cytokine help prevented the proper 




studies support the necessity of a functional and coordinated CD8 and CD4 T 
cell response for HBV control and clearance.  In addition to their discrete 
antiviral role, the humoral and cellular components of the adaptive immune 
system are also interconnected in a way that the failure of one of them clearly 
affects the expansion and protective efficacy of the other.  A lack of CD4 T cell 
help can impair CD8 T cell activity and antibody production 39, while the 
inability to mount a virus-specific CD8 T cell response results in a level of 
circulating virus that cannot be cleared by antibodies alone 40, supporting the 
notion of a complex interplay between the different components of the adaptive 
immunity. 
 
Considering the importance of T cells in HBV control and clearance, the T cell 
response greatly differs between patients with a self-limiting infection and those 
who develop chronicity.  Data from multiple groups have established the idea 
that chronically infected subjects are generally characterized by a weak or 
undetectable virus-specific T-cell response as opposed to acutely infected 
subjects where cytotoxic and helper T-cell responses are quantitatively stronger 
27-34.  Though the mechanisms responsible for the lowered T-cell response are 
not fully known, evidences favour the concept of anergy, exhaustion and 
deletion of HBV specific T-cells mediated by high doses of viral antigen 20, 35.  
In particular, two viral proteins regulated by the quantity of HBV replication 
have been shown to operate in this fashion.  HBeAg can suppress the immune 
response against HBcAg in adult T-cell receptor transgenic mice 41.  This cross-
reactivity of HBeAg can then delete or anergize HBcAg specific T-cells, thereby 




protein, HBsAg, might also suppress the immune response against HBV by 
acting as a high-dose tolerogen, as high serum levels of HBsAg are 
characteristic of chronically infected subjects 20, 42.  It is possible that this 
perpetually high antigen load can constantly activate the HBsAg specific T-cells 
causing activation induced deletion and anergy, resulting in the subnormal levels 
or sometimes absent HBsAg specific CD8+ T-cells in chronically infected 
subjects 31, 43.  It is important to note that other mechanisms, like the infiltration 
of T-regulatory cells into the liver 44, 45, dendritic cell defects 46-49, low level of 
MHC class I expression on hepatocytes 50 and the liver micro-environment, 
could also act in a non-mutually exclusive fashion and contribute to the 
dichotomous T cell response profile of acute and chronic HBV patients 20, 50.  




Even though there exists a wealth of information about the T cell response in 
HBV infection, some aspects are still unclear.  In particular, questions of 
immunodominance and immunoprotection remain unanswered.  This thesis will 
focus primarily on these two aspects.  Chapter 1 will discuss how host and virus 
variables influence the immunodominant hierarchy of the T cell response 30.  
More specifically, it describes the quantitative, functional and repertoire profile 
of HBV-specific T cells in a wide population of HBV infected Chinese and 
Caucasian patients.  This comparison demonstrates for the first time the 
similarities and differences in the HBV-specific T cell response profile of 




that 75% of chronic HBV patients reside in Asia 51.  Chapter 2 will cover the 
issue of immunoprotection during acute exacerbations of liver damage known as 
hepatic flares (HF) 52.  A longitudinal analysis of virological and immunological 
parameters, both cellular and secreted, performed during HF in chronic HBV 
patients allows for the understanding of immunological events that mediate HF 
and gives insight to the immunoprotective capacity of HBV-specific T cells 
during this pathological condition. 
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Figure 1.  Geographical distribution of HBV genotypes.  Genotypes B and C are most 
commonly found in Asia, while genotypes A and D are primarily associated with HBV 
infections in North America, Europe, Middle East and Russia.  Genotype E appears to be 
confined only to the African continent.  Adapted from: Kramvis et. al. (2005) 
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Figure 2.  Immunological progression of HBV infection.  The general pattern following 
HBV infection consists of three distinct phases: an asymptomatic latent phase, a viral 
replication phase and an adaptive immunity phase which is robust in acutely infected 
individuals but absent or weak in chronically infected patients.  Adapted from: Bertoletti 



























Virus-specific CD8+ T cells recognize virus encoded peptides associated with 
MHC class I molecules displayed on the surface of the infected cells.  Virally 
infected cells can produce thousands of potentially immunogenic peptides, but 
CD8+ T cells are usually directed against only a few peptides and CD8+ T cells 
specific for different viral determinants can possess different anti-viral activity 53.  
The information regarding virus-specific T cell repertoire and the potential 
antiviral efficacy of CD8+ T cells with differing antigen specificity is essential 
to understand viral pathogenesis and develop vaccines.  Such information is 
limited in the great majority of viral and bacterial infections due to cumbersome 
methods that are required for the detection and characterization of new MHC-
class I restricted epitopes 53.  In addition, the identification of the T cell 
repertoire against viruses infecting different ethnic populations with distinct 
HLA-class I alleles and haplotype frequencies is particularly complex because 
different ethnic groups are often infected by different viral strains, which is 
likely to have co-evolved in these populations 54-56.   
 
The influence that virus heterogeneity and the distinct HLA-profile of the 
infected subjects have on the repertoire and hierarchy of T cell responses is 
difficult to predict.  The existence of T cell responses against conserved regions 
of different virus strains 57, 58 and the reported degeneracy in HLA-peptide 
binding, with identical peptides able to bind multiple HLA-class I types 59-63, 
supports the idea of a substantial overlap in virus-specific T cell repertoire 
between subjects of different ethnicities expressing closely related, but distinct 
HLA-class I molecules.  On the other hand, viral heterogeneity might affect the 
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generation of certain epitopes as strain-specific variations within the epitopes 
64 or in flanking regions may impair their processing and presentation 65, 66.  
Even subtle differences in closely conserved HLA-class I molecules 63, 67 may 
severely affect the presentation of specific epitopes 68, 69 or change their 
conformation 70 sufficiently so that individuals of different ethnicity may focus 
the response towards different T cell epitopes.   
 
Given the global distribution of HBV, understanding the commonality or 
divergence of virus-specific T cell responses present in HBV infected patients 
with different ethnicities is necessary.  However, a comprehensive knowledge of 
HBV-specific CD8+ T cell specificities is lacking and, with rare exceptions 33, 71, 
72, CD8+ T cell responses have been analyzed primarily using pre-selected 
peptides able to bind to common HLA-class I molecules (HLA-A2, A3, A24, 
A11, B7) 28, 31, 72-77.  Furthermore, attempts to define immunodominant regions 
in the HBV proteome were based on the use of HLA-A2-restricted epitopes 31 
and on samples from HBVgenA (HBV genotype A) or HBVgenD (HBV genotype 
D) infected individuals of Caucasian decent.  Instead, 75% of the population of 
chronically infected patients live in Asia 51 and Asian patients are infected, 
mostly at birth, by HBVgenB (HBV genotype B) or HBV genC (HBV genotype C), 
which differ by nearly 8% in amino acid composition compared to genotypes A 
and D 16.   
 
Also, the HLA-class I profile of the two populations differ not only in the 
frequency of the major HLA class I alleles (i.e. HLA-A11 is present in 51.7% of 
Chinese and 14% of Caucasians; HLA-B40 is present in 31.5% of Chinese and 
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14.7% of Caucasians 67) but are also characterized by substantial differences 
in allele-subtypes.  The HLA-A2 molecule, present in nearly 50% of both 
Caucasians and Chinese, is subdivided in HLA-A2 subtypes, which are 
differentially expressed in the two ethnic groups 78.  More than 95% of HLA-
A2+ Caucasian are HLA-A0201+ whereas subtypes HLA-A0203, A0206 and 
A0207 are respectively present in 23%, 10% and 45% of HLA-A2+ individuals 
of Chinese origin 78.  Therefore, we performed the first direct comprehensive 
analysis of HBV specific T cell responses present in patients of different 
ethnicity (Chinese versus Caucasian) infected by different HBV genotypes 
(HBVgenB versus HBVgenD) to understand whether, and if so, to what degree host 
and virus variables influence the virus-specific T cell response. 
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MATERIALS AND METHODS 
Patient Selection.   
72 HBV infected patients of Chinese Han origin and 78 Caucasians of European 
descent were enrolled either at the Unit of Infectious Diseases and Hepatology 
of the Azienda Ospedaliero-Universitaria of Parma, Italy and the University 
Hospital S.Orsola-Malpighi of Bologna, Italy or at the National University of 
Singapore Hospital.  20 patients (8 Chinese and 12 Caucasians) had clinical, 
biochemical, and virological evidence of acute HBV infection (ALT levels >10 
times the upper limits or normal, detection of HBsAg and serum anti-HBc IgM 
and HBsAg clearance within 2 months from the clinical onset of hepatitis).  64 
HBV infected patients of Chinese origin and 66 of Caucasian origin displayed 
clinical, biochemical, and virological evidence of chronic hepatitis B infection 
(HBsAg and anti-HBc positive for at least 6 months), and displayed various ALT 
and HBV-DNA levels.  All patients were not under antiviral or 
immunomodulatory treatment during the study and 6 months before enrollment 
and all tested negative for HCV, HDV and HIV-1.   
 
HBV genotype characterization was performed on all patients enrolled.  Chinese 
HBV chronic patients infected with HBV genotype C (n=29) and 7 
undetermined patients were excluded from HBV-specific T cell analysis, while 
28 HBVgenB Chinese HBV chronic patients as well as 8 acute Chinese HBVgenB 
patients were selected for HBV-specific T cell analysis.  16 HBVgenA Caucasian 
patients were also excluded and 62 HBVgenD infected Caucasians were selected 
for further analysis.  HLA-A2 subtypes of HLA-A2 patients (selected by low 
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resolution genetic approach) were determined by high resolution sequencing 
of the A2 locus (direct sequencing of alpha 1 and alpha 2 chains).   
 
This study was approved by the Ethical Committee of the Azienda Ospedaliero-
Universitaria of Parma, the University Hospital of Bologna, and the NUH 
Ethical committee and all subjects gave written informed consent.   
 
Virological Assessment.   
HBsAg, HBeAg, anti-HBs, anti-HBc IgG and IgM, anti-HBe, anti-HDV, anti-
HCV and anti-HIV were determined by commercial enzyme immunoassay kits 
(Abbott Labs, IL, USA; Ortho Clinical Diagnostic, Johnson & Johnson, Raritan, 
NJ, USA, DiaSorin, Vercelli, Italy).  Serum HBV-DNA was quantified by PCR 
(Cobas Amplicor test; Roche Diagnostic, Basel, Switzerland).  HBV genotyping 
was performed by restriction fragment length polymorphism (RFLP) analysis of 
a pre-S amplicon previously described by Lindh et al 79. 
 
Synthetic Peptides and Antibodies.   
Two panels of 313 15-mer peptides overlapping by 10 residues were used to test 
HBV-specific T cell response.  The peptides covered the entire proteome of 
HBVgenD (accession number: AF121241) and HBVgenB (accession number: 
AF121243) and were purchased from Chiron Mimotopes (Victoria, Australia) or 
synthesized at the peptide synthesis facility of Massachusetts General Hospital 
using Fmoc chemistry.  Purity of peptides was above 80% and their composition 
was confirmed by mass spectrometry analysis.  The designed peptides present at 
least 95% similarity with HBV genomes sequenced from five Chinese and five 
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Caucasian patients studied.  15-mer core and X peptides were pooled in 9 by 8 
matrix containing 8 or 9 peptides/pool respectively using the similar concept  to 
what was previously described in HIV 80.  Envelope peptides were pooled in a 9 
by 9 matrix containing 9 peptides/pool; while polymerase peptides were pooled 
in a 14 by 12 matrix containing 12 or 14 peptides/pool respectively.  All peptides 
were first diluted at 40 mg/ml in DMSO and then further diluted in RPMI at 
working dilution (between 1 mg/ml and 1 ng/ml).   
 
Optimally defined HLA-A2 restricted CTL epitopes (Core18-27, Env183-91, 
Env335-43, Env338-47, Env370-79 and Pol455-63) of HBV genotype A, B, C 
and D were purchased from Proimmune (Oxford, UK) and from Gen Script 
(Piscataway, NJ, USA).  Peptide sequences were based on genotype specific 
sequences of 24 Gen Bank entries (6 HBVgenA, 8 HBVgenB, 6 HBVgenC, 4 
HBVgenD).  Furthermore, viral amino acid sequence analysis of Core18-27 and 
Env183-91 regions in the HLA-A2+ Chinese and Caucasian patients studied 
confirmed the genotype specific sequence of the infecting viral strain.  Anti-
CD8 (PE-Cy7), anti-CD3 (PerCP-Cy5.5) and anti-CD107a (FITC) antibodies 
were purchased from Becton Dickinson Pharmingen (San Jose, CA, USA).  
Anti-INF-PE was purchased from R&D Systems (Minneapolis, MN, USA). 
 
Isolation of PBMC and in vitro Expansion of HBV-specific CD8+ Cells.   
PBMC were isolated from fresh heparinized blood by Ficoll-Hypaque density 
gradient centrifugation and resuspended in AIM-V media (Invitrogen, Carlsbad, 
CA) with 2% pooled human AB serum (serum AIM-V).  For in vitro assays, 
cells were either used directly ex vivo or after a 10-day antigen-specific in vitro 
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stimulation.  For the latter, 20% of PBMC were first stimulated with 10 µg/ml 
of all the overlapping peptides from the respective HBV genotypes for an hour 
at 37°C, then washed and resuspended at 3.0 x 106 cells/ml before co-culturing 
with the remaining PBMC in serum AIM-V supplemented with interleukin-2 
(IL-2, R&D systems, Abingdon, UK) (20 IU/ml), seeded at 1 ml/well in 24-well 
plates.  The immunological assays were performed on day 10 of expansion.   
 
Intracellular Cytokine Staining (ICS) and Degranulation Assays.   
In vitro expanded PBMC were incubated in medium alone (control) or with viral 
peptides (5µg/ml) for 5 hours in the presence of brefeldin A (10 g/ml).  After 
washing, the cells were stained with anti-CD8 Pe-Cy7 and anti-CD3 PerCp-
Cy5.5 mAb for 30 min at 4°C and then fixed and permeabilized using 
Cytofix/Cytoperm™ Fixation/Permeabilization solution (BD Biosciences, San 
Jose, CA) according to the manufacturers instructions.  After fixation and 
permeabilization, cells were stained with anti-IFN- PE for 30 min on ice, 
washed, and analyzed by flow cytometry.  To assess degranulation activity, 
CD107a PE antibody (BD Pharmingen, San Diego) was added to all wells at the 
beginning of the 5 h incubation with T cells.  Following the incubation, cells 
were washed and labelled with anti-CD8 Pe-Cy7.   
 
CTL Clones and Epstein-Barr Virus (EBV) Transformed B Cell Lines.   
HBV Core18-27 specific CD8+ T cell clones were generated from HLA-A2+ 
HBV patients with acute hepatitis B as previously described 50.  EBV B cell 
lines with known HLA-A2 subtypes (kindly provided by Professor Chan Soh Ha, 
Department of Microbiology, National University of Singapore) were grown and 
Chapter 1 – Immunodominance of HBV-specific T cells (Materials and Methods) 
 
20
maintained in RPMI 1640 supplemented with 10% heat inactivated FBS, 20 
mM Hepes, 0.5 mM sodium pyruvate, 100 U/ml penicillin, 100 ug/ml 
streptomycin, MeM amino acids with L-glutamine, MeM non-essential amino 
acids (Invitrogen, Carlsbad, CA) and 5 ug/ml Plasmocin (InvivoGen, San Diego, 
CA) to prevent mycoplasma contamination. 
 
Interferon-Enzyme-Linked Immunosorbent Spot Assay (ELISPOT).   
IFN-ELISPOT assays were performed as previously described 33 using a panel 
of 313 overlapping peptides covering the entire proteome of HBVgenB or 
HBVgenD pooled in the described mixtures and used in patients infected with the 
respective HBV genotype.  HBV-specific T cell responses were analyzed in 
IFN- ELISPOT assays either ex vivo using fresh or frozen PBMC or after short-
term peptide-specific polyclonal T cell expansion (10 days).  Briefly, 96-well 
plates (Multiscreen-HTS Millipore, Billerica, MA) were coated overnight at 4°C 
as recommended by the manufacturer with 5 µg/ml capture mouse anti-human 
IFN- monoclonal antibody (1DIK, Mabtech, Sweden).  Plates were then 
washed 5 times with phosphate-buffered saline (PBS) and blocked with AIM-V 
supplemented with 10% heat inactivated fetal calf serum (FCS) for 30 minutes 
at room temperature.  1 x 105 PBMC or 5 x 104 cells from short-term polyclonal 
T cell lines were seeded per well, in duplicates for each individual peptide 
mixture.  Plates were incubated for 18 hours at 37°C in the presence or absence 
of peptides (at a final concentration of 5g/ml).  After washing five times with 
PBS, 100 µl of 0.5 µg/ml biotinylated anti-human IFN- monoclonal antibody 
(7B6-1, Mabtech, Sweden) was added and incubated for 2 hours at room 
temperature, thereafter washed 5 times and 100 µl of Streptavidin-alkaline 
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phosphatise (1:2000 dilution) (Mabtech, Sweden) was added to each well for 
one hour at room temperature.  Plates were again washed 5 times and 50 µl of 
alkaline phosphatase substrate (5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium chloride; BCIP/NBT, KPL, MD) was added.  After 10 to 15 minutes, 
the colorimetric reaction was stopped by washing with distilled water.  Plates 
were air-dried and spots were counted using an automated ELISPOT reader 
(Imunospot, CTL, OH).  IFN- producing cells was expressed as spot forming 
units (SFU) per 1 x 105 cells.  The number of specific IFN- secreting cells was 
calculated by subtracting the non-stimulated control value from the stimulated 
sample.  Positive controls consisted of PBMC stimulated with staphylococcal 
enterotoxin B (SEB) or phytohemagglutinin (PHA).  In the direct ex vivo assays, 
wells were considered positive when the SFU is above 5 and at least 3 times 
above the mean of unstimulated control wells (3 wells/patient).  Response to 
peptide mixtures was also analyzed directly ex vivo in 9 healthy subjects and 
only a single individual shows the presence of positive response.  The positivity 
criteria for in vitro ELISPOT assays is less stringent, including wells that have 
SFU of above 5 and at least 2 times above the mean of unstimulated control 
wells.  However, ICS was applied to every positive sample to reconfirm the 
response and to determine the T cell subset (CD8 or CD4) responsible for IFN- 
production. 
 
Image Analysis.   
A Series 3B ImmunoSpot Image Analyzer (Cellular Technology) specifically 
designed for the ELISPOT assay was used.  Digitized images were analyzed for 
the presence of areas in which colour density exceeds background by an amount 
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set on the basis of the comparison of wells with peptide and wells without 
peptide.  After background and noise subtraction, custom software is used to 
analyze spot morphology for circularity and density distribution to identify and 
separate touching and overlapping spots.  Objects that meet these criteria are 
recognized as spots and counted.  The measurement of mean spot size is a built-
in function of the software. 
 
Statistical Analysis.   
Unpaired t-test was used in two instances: 1) to determine the significance of the 
difference in the mean percentage of positive mixtures between acute and 
chronic patients, 2) to determine the significance of the difference in the 
ELISPOT assay derived mean spot size between acute and chronic patients 
stimulated with HBV peptides or SEB/PHA.  Differences with a P-value lesser 
than 0.05 were considered statistically significant. 
 
 




Comprehensive analysis of HBV-specific T cell responses in genotype B 
(HBVgenB) and genotype D (HBVgenD) HBV infected patients. 
To identify similarities/differences in the breadth and magnitude of HBV- 
specific T cell responses between Caucasian and Chinese patients, HBV-specific 
IFN-γ producing T cells were tested by direct ex vivo ELISPOT in 34 patients of 
Chinese origin (6 acute and 27 chronic HBVgenB infected) and in 37 Caucasian 
(4 acute and 33 chronic HBVgenD infected) subjects (Full clinical profile of all 
patients tested shown in Supplementary Table 1).  PBMC of Chinese patients 
were stimulated with the HBVgenB peptide panel, while Caucasian patients were 
stimulated with HBVgenD peptides.  Consistent with previous data obtained 
mainly in Caucasian patients 33, 71, HBV-specific T cell responses were detected 
ex vivo only in patients with acute HBV infection (6/6 Chinese and 4/4 
Caucasian subjects).  Responses in chronic patients (18% (5/27) of Chinese and 
15% (5/33) of all Caucasian individuals) were rarely observed ex vivo (Figure 1 
a and b), indicating that clinical status was a stronger predictor of detectable 
responses than ethnicity or infecting genotype.  In line with previous results 31, 
envelope-specific T cell response appears to be the only weak response 
detectable ex vivo in HBV chronic patients with high HBV load (Figure 1b).  
 
HBV-specific T cell responses were also compared after in vitro expansion in 17 
HBVgenB infected Chinese and 15 HBVgenD infected Caucasian subjects.  HBV-
specific T cell frequency was generally low directly ex vivo but became clearly 
detectable in all acute patients after in vitro expansion (Figure 2a), while such 
expansion was defective in chronic patients irrespective of ethnicity and HBV 
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genotype (Figure 2b).  Data for all patients is summarized in Figure 2c by 
comparing the number of peptide mixtures able to elicit an ELISPOT assay 
response in acute versus chronic HBV patients.  We observed the same general 
pattern of efficient expansion and multi-specific T cell responses in acute 
patients compared to weak and narrower T cell responses in chronic patients, 
irrespective of ethnicities and HBV genotypes.  Furthermore, previous reports 
suggested that magnitude of the HBV-specific T cell response is inversely 
correlated with the serum HBV-DNA level 31, 33, however, this relationship was 
not observed in our data, nor was there any correlation between HBV-specific T 
cell expansion and HBeAg/Anti-HBe status, probably attributable to the limited 
sample size(data not shown). 
 
Functional defects of HBV-specific T cells from chronic patients. 
Functional alteration of IFN-γ production by T cells has been reported in both 
Chinese 81 and Caucasian 33 chronic HBV patients.  While such defects were 
shown to be HBV-specific in Caucasians, a recent report suggested that T cell 
defects present in Chinese chronic HBV patients were pervasive and caused by 
PD-L1 up-regulation on dendritic cells 81.  To determine if there was an 
impairment of IFN-γ production in chronic HBV patients we examined the 
relative amount of IFN-γ secreted by HBV-specific and non-HBV specific T 
cells from healthy and HBV infected subjects.  Spot sizes 82 obtained in 
ELISPOT assays directly ex vivo in a total of 48 Chinese chronic patients (22 
HBV-DNA < 106, 26 HBV-DNA > 106), 4 patients with acute HBV infection 
and 9 healthy control subjects were measured.  The average spot size of non 
HBV-specific T cells (SEB stimulated) was similar across all groups and was 
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not influenced by HBV-DNA load (Figure 3a).  Identical results were 
obtained with in vitro expanded cells (Figure 3b), confirming that non-HBV 
specific T cell function was not affected by HBV status.  However, the average 
spot size of HBV-specific T cells was reduced nearly 50% in cells from chronic 
patients compared to individuals with resolved infection (p=0.016) (Figure 3b); 
demonstrating that the defect in IFN-γ production was selectively detectable in 
HBV-specific T cell populations of chronic patients.  
 
These results were validated by measuring the fluorescent intensity of IFN-γ+, 
HBV-specific T cells.  Representative results from one acute and one chronic 
patient are shown in Figure 3c.  The mean fluorescence intensity (MFI) of IFN-
γ+ HBV-specific cells detected in the acute and chronic patients differed 
significantly.  IFN-γ+ HBV-specific cells from acute patients had a high MFI 
(MFI=2104), while IFN-γ+ HBV-specific T cells from chronic patients had a 
low MFI and were often difficult to distinguish from un-stimulated cells.  Taken 
together, Chinese patients with chronic hepatitis B, like Caucasians 33, seem to 
harbor a functional T cell defect in IFN-γ production restricted to virus-specific 
cells. 
 
Ethnicity and HBV genotypes influence the HBV-specific CD8+ T cell 
repertoire of HBV infected patients.  
The above results show that neither race nor HBV genotype significantly 
influences the general quantitative and qualitative profile of the HBV-specific T 
cell response; however, these variables could still impact the diversity of the 
HBV-specific CD8+ T cell repertoire.  Therefore, we determined if ethnicity and 
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HBV genotype can influence CD8+ T cell responses against 6 HLA-A2 
restricted epitopes that have been previously shown to be promiscuously 
presented by multiple HLA-A2 subtypes (Table 1; 59).  High resolution HLA-
A2 typing was performed on the subjects to determine their HLA-A2 subtypes. 
All HLA-A2+ Caucasians were HLA-A0201, while HLA-A2+ Chinese patients 
displayed different HLA-A2 subtypes (A0201, n=3; A0203, n=5; A0206, n=4; 
A0207, n=8).  Patient PBMC were stimulated for 10 d with the peptides 
corresponding to the sequence of the infecting HBV genotype and the frequency 
of HBV-specific CD8+ T cells was analyzed by ICS for IFN-γ production. 
 
Figure 4 a and b shows the results of CD8+ T cell responses against Core18-27 
and Env183-91 peptides, which differ by one amino acid between HBVgenB/C 
and HBVgenA/D and frequently stimulate virus-specific CD8+ T cells in HLA-
A0201+ Caucasian HBV patients 31, 59, 83, 84.  As expected, 13/16 HLA-A0201+ 
Caucasian patients responded to the Core18-27(V) epitope.  In contrast, CD8+ T 
cells specific to Core18-27(I) were present in only 3/13 Chinese patients 
(Figure 4a).  Interestingly, none of the A201+ Chinese patients responded to 
HBVgenB/C Core18-27(I) and specific responses were only detectable in Chinese 
patients expressing HLA-A0207 (n=2) and HLA-A0206 (n=1).  
 
CD8+ T cell responses to Env183-91 epitope were highly influenced by HLA-
A2 micro-polymorphisms; 14/16 HLA-A0201+ Caucasian HBV patients 
responded to Env183-91(R) epitope from HBVgenA/D and 2/3 HLA-A0201+ 
Chinese patients (2/2 chronic patients) were capable of responding to the 
Env183-91(K) epitope from HBVgenB/C.  In contrast, all 11 Chinese patients 
Chapter 1 – Immunodominance of HBV-specific T cells (Results) 
 
27
expressing A0203, A0206 or A0207 HLA-A2 subtypes were unable to 
respond to the Env183-91(K) peptide (Figure 4b).  
 
Analysis of CD8+ T cell responses against epitopes conserved between 
HBVgenB/C and HBVgenA/D (out of 24 full HBV genomes entries of Gen Bank, see 
Material and Methods and Table 1.) confirmed the impact of HLA-A2 subtypes 
on the HBV-specific T cell repertoire.  While patients expressing HLA-A0201 
were capable of responding to Pol455-63, Env335-43, and Env348-57 epitopes 
(Figure 4c), only sporadic promiscuous responses could be detected in other 
HLA-A2 subtypes; one HLA-A0206+ patient (Env338-47), two in HLA-
A0207+ patients (Env338-47 & Env335-43) and one in a HLA-A0203+ patient 
(Env348-57).  Responses to the Pol455-63 epitope, which was targeted by 6/8 
HLA-A0201+ subjects, were not seen at all in HLA-A0201 negative individuals 
(Figure 4c).  Conversely, responses to Env338-47, a peptide with only predicted 
HLA-A2 -binding ability 84, were present in HLA-A0206 and HLA-A0207 acute 
subjects but undetectable in all HLA-A0201+ subjects tested.  
 
Hierarchy of HBV-specific CD8 T cells in HLA-A0206 and HLA-0203 
patients 
We then investigated whether the HBV-specific CD8+ T cell repertoire of 
Chinese patients expressing different HLA-A2 subtypes focused on specificities 
which differ from those previously defined in A201+ Caucasian patients.  To 
avoid the bias associated with focusing on previously identified epitopes, HBV-
specific T cell responses were assessed using 15-mer overlapping peptides 
covering the entire HBV proteome, followed by characterization of fine 
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specificity and HLA-restrictions of detectable responses.  Given the extensive 
cell requirements for such comprehensive analyses, we were able to perform 
such thorough analysis in one HLA-A0206 and one HLA-A0203 patient with 
acute HBV infection.  In the HLA-A0206+ acute HBV patient, 3 responses were 
found directly ex vivo with a dominant response targeting a region of the core 
protein (Figure 5a).  Detailed analysis of the phenotype, fine specificity and 
HLA-restriction of the responsive T cells revealed that this response recognized 
a novel HLA-A0206 -restricted Core8-16 (EFGASVELL) epitope (data not 
shown).  The two additional responses present at lower frequencies were 
directed against a second region in core and one in envelope which did not 
overlap with the previously known A2 epitopes (Figure 5a).  
 
Responses against “promiscuous” HLA-A2 epitopes were also analyzed but 
were not detected directly ex vivo (data not shown).  However, after in vitro 
stimulation using the corresponding optimal HLA-A2 peptides, the A0206+ 
acute patient demonstrated the presence of Core18-27(I) (HBVgenB/C) and 
Env335-43 CD8+ response, which were sub-dominant in terms of frequency 
compared to the Core8-16 specific CD8+ response (Figure 5b).  
 
The A2-restricted CD8+ T cell repertoire in the HLA-A0203+ patient differed 
significantly from that of the HLA-A0206 patient.  Analysis of HBV-specific 
CD8+ T cell repertoire was performed only after in vitro expansion and it 
revealed the presence of a HLA-A0203-restricted response to two HBV epitopes 
rarely recognized in Caucasian subjects (Env370-79 and Pol504-12; Figure 5b).  
Responses against all other known HLA-A2 -restricted HBV epitopes were 
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undetectable, both directly ex vivo and after in vitro expansion (data not 
shown and Figure 5b).  These results confirm that the HLA-A2 polymorphisms 
in the Chinese subjects lead to a different focus of the HLA-A2- restricted 
responses compared to the response patterns seen in the HLA-A0201 Caucasian 
population. 
 
The effect of HBV genotype and HLA-A2 subtypes on CTL recognition. 
To further dissect how the combination of amino acid differences in HBV 
genotypes and HLA-A2 subtypes influence CD8+ T cell response patterns, we 
assessed the recognition of genotype-specific epitope variants in the context of 
several HLA-A2 subtypes.  Core18-27 specific CD8+ T cell clones generated 
from an A201+ HBV infected patient can efficiently recognize the Core18-27(I) 
peptide variant when presented by different A2 subtypes (Figure 6).  Peptide 
recognition was effective in the context of HLA-A0206, A0207 and A0201 
positive EBV transformed B cell lines, which trigger CD8+ T cell activation 
when pulsed with low (10pM) concentrations of Core18-27(I) peptide.  Instead, 
only minimal CD8+ T cell activation was observed after stimulation with 
peptide loaded HLA-A0203+ target cells, even at the highest peptide 
concentration (100 nM; Figure 6).  
 
We then analyzed, in parallel, the ability of HLA-A2 subtypes to present the two 
genotype-specific Core18-27 epitope variants as well as the stability of the 
peptide/HLA-A2 complex, a parameter associated with peptide immunogenicity 
85.  Antigen presenting cells with defined HLA-A2 subtypes were pulsed with 
increasing concentrations of Core18-27(V) or Core18-27(I) peptides and then 
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used to stimulate Core18-27(V)-specific CD8+ T cell clones.  Effector cells 
were added immediately or after a 12 hour period.  Both the Core18-27(V) as 
well as its 27(I) variant peptide were presented effectively by HLA-A0201, 
A0206 and A0207 but not by A0203 if effector cells were added immediately.  
However, when the loaded peptides were allowed to dissociate from the antigen 
presenting cells before addition of the effector T cells (after a 12 h period), the 
Core18-27(I) variant was in all cases less stimulatory than the Core18-27(V) 
peptide.  In the context of HLA-A0201, the genotype B Core18-27(I) peptide 
lost essentially all immunogenicity, whereas immunogenicity was retained when 
the Core18-27(I) peptide was presented by HLA-A0206.  Not surprisingly, the 
little stimulatory efficiency of HLA-A203+ targets was completely lost after the 
12 h dissociation period (Figure 7).  It is interesting to note that the peptide 
presentation data recapitulate the frequency of Core18-27 specific CD8+ T cells 
detected in HBV infected patients.  The hierarchy of Core18-27(I) presentation, 
(A0206>A0207>A0201>A0203) described by the presentation experiments in 
Figure 7 are in line with the presence of Core18-27(I)-specific CD8+ T cell 
responses found in some HLA-A0206 and A0207 HBV patients and their 
absence in HLA-A0201 and A0203 patients (Figure 4a).  
 
Finally, we tested whether HBVgenB infected Asian individuals could recognize 
epitope variants from HBVgenD.  T cell lines specific for different HBVgenB 
epitopes were generated from Chinese individuals with acute HBVgenB infection 
and tested for recognition of epitope variants naturally present in genotypes D, 
A and C.  The single amino acid substitution within the Core8-16 peptide 
(S12T) did not affect Core8-16 specific CD8+ T cell recognition (Figure 8).  
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Similarly, despite the presence of 3 different amino acids, the peptide 
corresponding to the sequence Env370-79 of HBVgenA/D was recognized, even 
though to a lesser degree, by the Env370-79 HBVgenB specific HLA-A0203-
restricted CD8+ T cell line.  In contrast, the single amino acid difference present 
in the HBVgenC (S373N) variant completely abolished CD8+ T cell recognition 
(Figure 8).  Whether such amino acid substitution (S373N) abolish the HLA-
A203 binding ability of the peptide or instead altered the T cell receptor 
recognition site will need to be properly analyzed.   
 
 




In this study, we took advantage of the segregation of different HBV genotypes 
in geographically and genetically distinct host populations to directly analyze 
the impact that host and virus variables exert on the virus-specific T cell 
response.  Two important points emerged: a) HBV-specific T cell quantity is 
determined by the virological and clinical profile of the patients, which 
outweighs any influence of race or viral diversity; b) HBV-specific T cell 
repertoire is divergent in the two ethnic groups with T cell epitopes frequently 
found in Caucasian patients seldom detected in Chinese patients.   
 
In Asia, chronic HBV infection is mainly derived from vertical infection at birth 
86 whereas horizontal transmission (household/sexual contacts) is the likely 
route of infection in Caucasians.  In addition, infection by different HBV 
genotypes has also been suggested to influence clinical outcomes or disease 
severity 15.  Furthermore, by inference from HCV infection, host ethnicity may 
impact clinical parameters and antiviral CD4+ T cell response 87.  To our 
knowledge, whether these epidemiological variables might alter the profile of 
the HBV-specific T cell response has never been directly tested.  Our results 
show that the epidemiological variables characteristic of the different ethnic 
populations do not impact the overall virus-specific T cell quantity.  Rather, the 
level of the cellular immunity appears largely defined by the clinical status of 
the tested patient.  HBV-specific T cells were easily detected directly ex vivo 
only in acute patients while HBV-specific T cell responses were very weak in 
chronic patients.  Although different HBV genotypes or transmission routes 
could trigger different pathogenic mechanisms resulting in viral persistence, our 
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data indicate that the ability to control HBV or conversely, HBV persistence, 
results in a highly similar quantitative profile of HBV-specific T cell responses, 
irrespective of ethnicity and HBV genotype.   
 
We also confirmed, by analyzing IFN-γ production at a single cell level, that 
HBV-specific T cells of Chinese chronic patients infected by HBVgenB were 
defective for IFN-γ production.  The IFN-γ defect was found exclusively in 
HBV-specific T cells while the general T cell population was unaffected.  While 
this finding is in contrast with recent data 81 where apparent up-regulation of 
PD-L1 on myeloid dendritic cells has been implicated in suppressing global T 
cell function, the data confirm results obtained in anti-HBe+ Caucasian patients, 
where the impairment of IFN-γ production, restored by blocking PD-1/PD-L1 
(Programmed death 1 / Programmed death 1 ligand), was restricted to HBV-
specific T cells 33.   
 
HBV genotypes and the individuals’ genetic background instead play an 
important role in shaping the HBV-specific T cell repertoire.  We found that 
HLA-A2 restricted CD8+ T cell epitopes which frequently induced responses in 
HLA-A0201 Caucasian patients and possess “HLA-class I super-type” binding 
capacity 59, are scarcely (Core18-27) or completely unable (Env183-91, Pol455-
65) to induce CD8+ T cell responses in HLA-A0206, A0207 or A0203 Chinese 
patients.  Furthermore, a comprehensive analysis of the CD8+ T cell repertoire 
performed in one HLA-A0206 and one HLA-A0203 HBV patient directly 
confirmed, in naturally infected subjects, how HLA-micro-polymorphisms 
(HLA-A0206/A0207 and A0203 differ from A0201 by a single or three amino 
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acid respectively) and viral amino acid differences impact CD8+ T cell 
responses.  These two subjects preferentially focused T cell responses on HLA-
A2-restricted epitopes never (Core8-16 and Pol406-12) or scarcely (Env 371-79) 
88 detected in HLA-A0201 subjects, while responses to classical HLA-A2 
restricted epitopes were not at all (HLA-A0203 patient) or rarely (HLA-A0206 
patient) present.   
 
The discordance of HBV-specific CD8+ T cell repertoire in the two ethnicities 
is not surprising if one considers the different mechanisms that might alter 
immunogenicity of antigenic peptides.  For example, the ability of a peptide 
epitope to induce CD8+ T cells can be influenced by its bound conformation 
without necessarily altering the HLA-binding ability.  Work in EBV infection 
has shown that the conformational changes imposed by a single amino acid 
variation present in two closely related HLA-class I molecules (HLA-B3501 & 
HLA-B3508) are sufficient to alter the ability of an identical peptide to induce a 
CTL response 70.  This scenario might explain our inability to detect HBV 
Pol455-63 epitope in HLA-A0203, A0206 and A0207 patients, despite its 
conservation between different genotypes and its reported “promiscuous” ability 
to bind different HLA-A2 subtypes 59.  Furthermore, the ability of HLA-A2 
subtypes to preferentially present different sets of peptides 68, 69 is another 
important contributor of the distinct epitopes targeted in HBV patients 
expressing different HLA-A2 subtypes.  In addition to the alterations imposed 
by the HLA-A2 polymorphisms, the presence of distinct HBV genotypes in 
different ethnicities can further increase the potential diversity in the pool of 
immunogenic peptides.  HBV genotypes differ approximately 8% in their amino 
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acid composition 16, and so it is likely that HBV genotype amino acid 
variations located within or just outside HBV epitopes might modify epitope 
processing, presentation or recognition 65, 66. 
 
Our experiments prove that these amino acid variations can affect T cell 
recognition of CD8 specific T cell epitopes.  In particular, we showed for the 
Core18-27 epitope, that the presence of isoleucine instead of valine at position 
27 reduced the stability of peptide/HLA-A2 complex to varying degrees in all 
HLA-A2 subtypes tested.  The Core18-27 isoleucine variation is characteristic 
of HBVgenB/C and our findings help explain the generally poor immunogenicity 
of the Core18-27(I) epitope in HLA-A0201+ Chinese subjects.  At the same 
time, the observation that the HBVgenB/C Core18-27(I) peptide is more stably 
presented by HLA-A0206 and A0207 (only expressed by Chinese patients) than 
HLA-A0201 is puzzling.  While it could be driven by a possible host-virus co-
evolution, its evolutionary significance is obscure as such co-evolution would 
have led to the conservation of a highly avid epitope presented by some of the 
dominant HLA alleles.  Whether this finding can be extrapolated to other 
epitopes and whether or not these responses are significantly involved in viral 
control clearly requires broader analyses in larger cohorts and more diverse 
HLA backgrounds.   
 
In conclusion, ethnic and viral differences do not alter the vigor of HBV-specific 
T cell responses present in patients with HBV infection but these variables 
shape distinct HBV-specific T cell repertoires.  Results from our findings show 
a limited contribution of HLA-A2 “promiscuous” HBV epitopes to the HBV 
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specific CD8 T cell repertoire of ethnically different patients and questions, at 
least in the context of HLA-A2 allele, the ability of the supertype motifs to 
predict virus-specific CD8+ T cell responses present in different ethnic groups.  
From our data it seems clear that HBV-specific immune monitoring in Asian 
patients should not rely on the exclusive analysis of epitopes found in 
Caucasians or conformed to algorithms that do not consider the clustering of 
different viral strains within different ethnic groups.  Furthermore, the use of 
polyepitope vaccines 89, based on peptides selected by HLA-class supermotifs or 
on responses found in Caucasian patients might divert the response towards 
incorrect specificities, stimulating non-natural responses which might be 
functionally incapable of recognizing the infectious virus, a situation that has 
already been reported in HIV infections 90, 91.  However, it must also be 
considered that predicted epitopes that might not be naturally immunogenic can 
be advantageous in breaking immunological tolerance caused by persistent virus 
infection; potentially expanding non-tolerized, cross-reactive CD8 T cells able 
to recognize the infecting virus with therapeutic advantage 88.  T cell repertoires 
elicited by vaccines and their therapeutic effects in patients will have to be 
carefully analyzed in patients to resolve this conundrum and shed further light in 
the complex and fascinating diversity of the anti-viral T cell response in humans. 
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Genotype B Genotype D Chinese Caucasian Chinese Caucasian Chinese Caucasian
Envelope
Env 183-191* FLLTKILTI FLLTRILTI 0 / 5 7 / 8 2 / 8 7 / 8 0 / 6 2 / 9
Env 335-343* WLSLLVPFV WLSLLVPFV 1 / 5 4 / 6 0 / 8 1 / 8 0 / 6 0 / 9
Env 338-347 LLVPFVQWFV LLVPFVQWFV 2 / 5 0 / 6 1 / 8 1 / 8 0 / 6 1 / 9
Env 348-357 GLSPTVWLSV GLSPTVWLSV 1 / 5 4 / 7 0 / 8 3 / 8 0 / 6 1 / 9
Polymerase
Pol 455-463* GLSRYVARL GLSRYVARL 1 / 5 5 / 7 0 / 8 1 / 8 0 / 6 0 / 9
Core
Core 18-27* FLPSDFFPSI FLPSDFFPSV 2 / 5 7 / 8 1 / 8 6 / 8 0 / 6 0 / 9








Table 1.  Tabulated summary of CD8+ T cell responses against known HLA-A2 
restricted epitopes in HLA-A2+ Chinese and Caucasian patients.  PBMC from HLA-
A2+ Caucasian and Chinese acute or chronic patients (segregated by HBV-DNA levels) 
were expanded in vitro for 10 d and tested against known HLA-A2 restricted HBV epitopes. 
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Figure 1.  Ex vivo quantitative profile of HBV-specific T cells in Chinese and 
Caucasian HBV patients.  A). Overlapping peptide pools were used to stimulate PBMC 
directly ex vivo in the IFN-γ ELISPOT assay.  Results of selected acute and chronic Chinese 
and Caucasian patients, segregated based on HBV-DNA and ALT levels (shown above 
figures) are displayed.  Each bar represents the response to an individual peptide mixture.  
B) Mean ex vivo frequency of IFN-γ producing cells in patients of different ethnicity.  Each 
bar represents the response to the mixtures covering the indicated HBV protein with error 
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Figure 2.  Quantification of HBV-specific T cells after in vitro expansion.  A) and B) 
ELISPOT analysis was performed on PBMC directly ex vivo (above) and after 10 d of in 
vitro expansion (below) using the same pools of peptides.  Two selected acute (A) and 
chronic (B) are displayed.  Each bar represents the response to an individual peptide 
mixture.  The threshold of positivity (above 5 SFU and 2 times above the mean SFU of 
unstimulated control) is indicated as a dashed bar.  C) Each bar represents the percentage of 
positive mixtures observed from the ELISPOT assays after in vitro expansion in the 
different categories (n indicates the number of patients tested in each category).  Acute and 
chronic Chinese and Caucasian patients were segregated based on HBV-DNA levels (Chr-
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Figure 3.  Quantification of IFN-γ production in acute and chronic Chinese patients.  
The mean spot size of the positive wells in the ELISPOT assay was used as an estimate of 
the quantity of IFN-γ produced by single cells after stimulation.  A) Direct ex vivo 
quantification of unicellular IFN-γ production in healthy, acute and chronic Chinese patients 
after SEB stimulation.  Each bar represents the mean spot size with error bars indicating the 
standard error of the mean.  B) Quantification of unicellular IFN-γ production in acute and 
chronic Chinese patients after 10 d of in vitro expansion.  Only significant differences are 
shown (HBV-specific: Acute patients VS Chronic patients; [MeanSEM] 10.90.7 VS 
6.91.0 10-2 mm2).  C) IFN-γ production by HBV-specific CD8 T cells determined by ICS.  
A representative acute and a chronic HBV infected Chinese patient are shown.  The 
percentages of IFN-γ+ cells out of the CD8+ cells after gating on the CD3+ fraction of 
PBMC and the mean fluorescence intensities (MFI) of the double positive population are 
indicated.  Cells incubated without the HBV polymerase peptide pool were used as the 
unstimulated negative control in which the IFN-γ+ gate was set. 
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Figure 4.  Induction of CD8+ T cell response against known A2-restricted epitopes in 
HLA-A2+ Oriental and Caucasian patients.  Bars represent the frequency of Core18-27 
(A) or Env183-91 (B) specific CD8+ T cells in individual patients with the indicated HLA-
A2 subtypes.  PBMC of Chinese patients were expanded with HBVgenB/C Core18-27(I) or 
Env183-91(K) peptide while PBMC of Caucasian patients were expanded with HBVgenA/D 
Core18-27(V) peptide or Env183-191(R) (all at 1µM) for 10 d, before re-stimulating the 
lines with the corresponding stimulatory peptide and analyzing the frequency of CD8+ cells 
producing IFN-γ with ICS.  Sequencing of Core18-27 region of HBV virus infecting the 
chronic Chinese and Caucasian patients confirm the presence of Core18-27(I) and Core18-
27(V) sequence in the Chinese in Caucasian patients respectively.  The hatched line 
demarcates the A0201 expressing subjects.  C) Frequency of CD8+ T cell response against 
conserved HBV epitopes (Genotype B = Genotype D) Pol456-63, Env338-47, Env335-43 
and Env348-57 in acute Chinese and Caucasian HBV patients. 
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Figure 5.  Hierarchy of HBV-specific CD8+ T cell response in a HLA-A0206 and a 
HLA-A0203 Chinese acute HBV patient.  A) Direct ex vivo ELISPOT frequency of HBV-
specific T cells in the PBMC of a HLA-A0206+ acute patient.  Triplicate wells of 
unstimulated cells gave a mean of 3 spots/well of background.  B) Frequency of CD8+ T 
cells specific for the indicated peptides in the HLA-A0206 and HLA-A0203 patients tested 
after in vitro expansion.  Bars represent the frequency of peptide-specific CD8+ T cells after 
in vitro expansion. 
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Figure 6.  Functional presentation of Core18-27 by HLA-subtypes common in the 
Chinese population.  Frequency of CD107a+ or IFN-γ+ CTLs after stimulation with EBV 
B cell lines, expressing the various HLA-A2 subtype molecules (HLA-A0201, A0206, 
A0207 and A0203), pulsed with graded concentrations of HBVgenB/C Core18-27(I).  The 
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Figure 7.  Time course analysis of Core18-27 epitope presentation by HLA-A2 
subtypes.  Frequency of IFN-γ+ CTLs tested with EBV B cell lines, expressing HLA 
A0201, A0206, A0207 and A0203, pulsed with graded concentrations of HBVgenB/C Core 
18-27(I) or HBVgenA/D Core18-27(V).  The different EBV B cells were pulsed with the 
peptides for 30 minutes and co-incubated with the CTL lines either immediately or after 12 
hours of in vitro resting.  Bars represent the frequency of activated CTLs tested against 
targets pulsed with Core18-27(V) (black) or Core18-27(I) (white).  Similar results were 
obtained measuring CD107a expression (not shown). 
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Figure 8.  Influence of amino acid variations within different genotypes in T cell 
recognition.  T cell lines specific for different HBVgenB encoded epitopes were expanded 
from acute patients of Chinese origin (Genotype B infected).  The T cell lines indicated 
were stimulated with peptides corresponding to the different genotypes for 5 hours and 
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SUPPLEMENTARY TABLES AND FIGURES 
 
Patient Ethinicity HBV 
Genotype
Infection Status HBeAg Anti-HBe HBV DNA (copies/ml) ALT 
(IU/ml)
AR1 Chinese - Acute/Res - - - 19
AR2 Chinese - Acute/Res - - - 2830
AR3 Chinese - Acute/Res - - 500,000 1878
AR4 Chinese - Acute/Res - - - -
AR5 Chinese - Acute/Res - - - -
AR6 Chinese - Acute/Res - - - 1894
AR7 Caucasian - Acute/Res - - 121,000 1107
AR8 Caucasian - Acute/Res - - 1,772,000 3563
AR9 Caucasian - Acute/Res - - 75,200 1712
AR10 Caucasian - Acute/Res - - 21,800 1118
CH1 Chinese B Chronic NRCT RCT 1,397 24
CH2 Chinese B Chronic NRCT RCT 1,736 53
CH3 Chinese B Chronic NRCT RCT 2,440 38
CH4 Chinese B Chronic NRCT RCT 2,804 47
CH5 Chinese B Chronic NRCT RCT 2,960 37
CH6 Chinese B Chronic NRCT RCT 3,000 -
CH7 Chinese B Chronic NRCT RCT 4,240 41
CH8 Chinese B Chronic NRCT RCT 6,366 35
CH9 Chinese B Chronic NRCT RCT 10,000 36
CH10 Chinese B Chronic NRCT RCT 10,321 27
CH11 Chinese B Chronic RCT NRCT 30,000 30
CH12 Chinese B Chronic NRCT RCT 100,000 15
CH13 Chinese B Chronic NRCT RCT 150,000 27
CH14 Chinese B Chronic NRCT RCT 1,000,000 41
CH15 Chinese B Chronic NRCT RCT 2,000,000 69
CH16 Chinese B Chronic NRCT RCT 6,100,000 160
CH17 Chinese B Chronic RCT NRCT 7,500,000 66
CH18 Chinese B Chronic RCT NRCT 10,000,000 814
CH19 Chinese B Chronic RCT NRCT 22,200,000 40
CH20 Chinese B Chronic NRCT RCT 61,000,000 53
CH21 Chinese B Chronic RCT NRCT 340,000,000 58
CH22 Chinese B Chronic RCT NRCT 604,000,000 58
CH23 Chinese B Chronic RCT NRCT 1,000,000,000 136
CH24 Chinese B Chronic RCT NRCT 1,500,000,000 129
CH25 Chinese B Chronic RCT NRCT 2,000,000,000 43
CH26 Chinese B Chronic RCT NRCT 2,100,000,000 311
CH27 Chinese B Chronic RCT NRCT 7,300,000,000 108
CH28 Caucasian D Chronic NRCT RCT 700 -
CH29 Caucasian D Chronic NRCT RCT 1,000 -
CH30 Caucasian D Chronic NRCT RCT 1,000 -
CH31 Caucasian D Chronic NRCT RCT 1,000 -
CH32 Caucasian D Chronic NRCT RCT 3,162 -
CH33 Caucasian D Chronic NRCT RCT 97,800 25
CH34 Caucasian D Chronic NRCT RCT 122,000 24
CH35 Caucasian D Chronic NRCT RCT 158,000 38
CH36 Caucasian D Chronic NRCT RCT 240,000 126
CH37 Caucasian D Chronic NRCT RCT 280,000 -
CH38 Caucasian D Chronic NRCT RCT 358,000 37
CH39 Caucasian D Chronic RCT NRCT 400,000 -
CH40 Caucasian D Chronic NRCT RCT 1,000,000 -
CH41 Caucasian D Chronic NRCT RCT 2,700,000 43
CH42 Caucasian D Chronic RCT NRCT 10,000,000 -
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Supplementary Table 1.  Clinical profile of patients tested directly ex vivo using the 
Elispot assay.  Detailed profile of patients that have been tested directly ex vivo in Figure 
1b.  Chinese patients that are infected with HBV genotype C have been excluded from the 







Patient Ethinicity HBV 
Genotype
Infection Status HBeAg Anti-HBe HBV DNA (copies/ml) ALT 
(IU/ml)
CH43 Caucasian D Chronic RCT NRCT 10,000,000 -
CH44 Caucasian D Chronic RCT NRCT 10,000,000 -
CH45 Caucasian D Chronic RCT NRCT 10,000,000 -
CH46 Caucasian D Chronic RCT NRCT 10,000,000 -
CH47 Caucasian D Chronic RCT NRCT 10,000,000 -
CH48 Caucasian D Chronic RCT NRCT 10,600,000 109
CH49 Caucasian D Chronic RCT NRCT 13,150,000 65
CH50 Caucasian D Chronic RCT NRCT 17,000,000 -
CH51 Caucasian D Chronic RCT NRCT 21,000,000 -
CH52 Caucasian D Chronic RCT NRCT 44,500,000 144
CH53 Caucasian D Chronic RCT NRCT 65,000,000 60
CH54 Caucasian D Chronic RCT NRCT 77,100,000 138
CH55 Caucasian D Chronic RCT NRCT 100,000,000 -
CH56 Caucasian D Chronic RCT NRCT 470,000,000 -
CH57 Caucasian D Chronic RCT NRCT 676,000,000 -
CH58 Caucasian D Chronic RCT NRCT 800,000,000 -
CH59 Caucasian D Chronic RCT NRCT 860,000,000 -
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Chronic hepatitis B is a heterogeneous disease which afflicts many world-wide.  
Patients persistently infected by HBV present markedly different levels of HBV 
replication (from undetectable levels to 1011 HBV-DNA copies/ml of serum) 
and often alternate periods of absence of liver inflammation and severe hepatitis 
92.  These acute exacerbations of liver damage (called hepatic flares, HF) can 
occur spontaneously, be induced by IFN-α therapy or by the withdrawal of 
treatment with nucleoside analogues 93.  They are often preceded by high levels 
of HBV replication and by progressive accumulation of HBV antigens 94.   
 
Since HBV is not a directly cytopathic virus, an increase in virus-specific T cell 
response has been conventionally thought of as the direct cause of liver damage.  
As such, the prevailing idea is that HF are the result of a robust quantitative 
recovery of HBV-specific T cells which directly cause the liver injury 93.  
However, there is scarce experimental evidences to support such a scenario, 
which is limited to data showing a reconstitution of HBV-specific helper T cell 
response occurring after the pathogenic event 95.  In contrast, increases in HBV-
specific CD8 T and CD4 T cell quantities are preferentially associated with 
virus control rather than liver damage 31, 96 and work in animal models 97, 98 and 
patients 96 have shown that the antigen non-specific inflammatory mononuclear 
infiltrate is the principal factor responsible for liver injury.   
 
In animals, HBV-specific CD8 T cells or NK cells trigger inflammatory events 
through the involvement of different cell types (granulocytes and platelets) and 
production of chemokines (CXCL-9, CXCL-10) 99, but data in HBV infected 
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patients is scarce.  To obtain a better understanding of the immunological 
mechanisms involved in the pathogenesis of HF we studied chronic HBV 
patients with spontaneously occurring or antiviral withdrawal induced HF as 
well as classical acute HBV patients.  Therapy withdrawal caused, in a precise 
chronological order, a rebound of HBV replication followed, after a consistent 
time lapse (12-16 weeks), by a HF.  We then studied a composite array of 
immunological parameters in the serum and PBMC of patients before and 
during HF and during infection phases when HBV rebound and liver 
inflammation were uniquely separated.  This allowed us to answer the following 
questions of immunoprotection: a) Is HBV replication rebound associated with 
activation of innate or adaptive immunological events?; b) Are HF associated 
with recovery of HBV-specific immunity or with activation of other components 
of innate immunity (NK and regulatory cells)? 
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MATERIALS AND METHODS 
Patients 
44 patients with HBV infection were studied.  5 HBV chronic patients were 
studied for about 1 year at monthly intervals.  They were under antiviral 
treatment within a Phase III trial to evaluate the efficacy of an analogue of 
Adefovir (Remofovir).  Due to reports of possible renal toxicities with 
prolonged Remofovir treatment, the patients opted for therapy interruption 
under close clinical monitoring.  These 5 patients had clinical and virological 
evidence of chronic HBV infection (hepatitis B surface antigen (HBsAg) 
persistence for over 6 months; HBV-DNA > 107).  5 patients with acute hepatitis 
B (ALT levels at least 10 times the upper limit of normal, ≥ 700 IU/ml, 
detection of HBsAg and serum anti-hepatitis B core antigen IgM, and HBsAg 
clearance within 2 months from clinical onset of hepatitis) were also studied at 
different time points at the onset of disease and after disease resolution.  
Additional 34 patients with chronic hepatitis B were studied cross-sectionally 
(single time point).  12 healthy subjects were recruited as controls.  All studied 
patients/subjects were negative for antibodies to hepatitis C virus (HCV), delta 
virus, human immunodeficiency virus type 1 (HIV-1).  The study was approved 
by the Singapore Ethics Committee,  
 
Virological Measurements 
HBsAg, HBeAg, anti-HBs, anti-HBc IgG and IgM, anti-HBe, anti-HDV, anti-
HCV, anti-HIV-1 and -2 were determined by commercial enzyme immunoassay 
kits (Abbott Labs, IL, USA; Ortho Clinical Diagnostic, Johnson & Johnson, 
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DiaSorin, Vercelli, Italy).  Serum HBV-DNA was quantified by PCR (Cobas 
Amplicor test; Roche Diagnostic, Basel, Switzerland). 
 
Determination of cytokine/chemokine concentrations 
Patient sera were tested for pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), 
the immune-regulatory cytokine (IL-10), a neutrophil chemo-attractant (CXCL-
8), and chemokines (CCL-2, CXCL-9 and CXCL-10) using the Cytometric 
Bead Array System (BD Biosciences, San Jose, CA) according to the 
manufacturer’s protocol.  CCL-3 levels were measured using the Bioplex system 
(Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s protocol.  
Serum IFN-α was assayed using the ELISAPRO kit (Mabtech, Sweden) according 
to the manufacturer’s protocols.   
 
Direct ex vivo staining of NK cells and Treg 
For NK cell staining, PBMC from chronic HBV patients were incubated for 30 
mins at 4C with anti-CD3-PerCpCy5.5, CD56-APC and TRAIL-PE mAbs (BD 
Biosciences, San Jose, CA).  For Treg staining, PBMC from chronic patients 
were incubated for 20 mins at room temperature in the dark with anti-CD4-
PeCy7, CD25-APCCy7 and CD39-PE (BD Biosciences, San Jose, CA).  The 
cells were fixed and permeabilized using the Human FoxP3 Buffer Set (BD 
Biosciences, San Jose, CA) according to the manufacturer’s instructions.  
Isotype-matched control antibodies were used to define the positive staining 
populations.  Cells were acquired on a FACS Canto flow cytometer. 
 
Chapter 2 – Immunoprotection of HBV-specific T cells (Materials and Methods) 
 
53
Direct ex vivo quantification of HBV-specific T cells.  
PBMC were incubated with AIM-V + 2% human AB serum (Invitrogen, 
Carlsbad, CA) alone (as control), or stimulated with overlapping peptide pools 
covering the entire proteome of HBV genotype B (accession number: 
AF121243) at a concentration of 2 g/ml per peptide in the presence or absence 
of 10 g/ml anti-PD-L1 mAb (eBioscience, San Diego, CA) for 5 h using 10 
g/ml brefeldin A (Sigma-Aldrich, St. Louis, MO) as protein secretion inhibitor.  
Anti-CD107a-PE mAb (BD Biosciences, San Jose, CA) was added to all wells 
at the beginning of the 5 h incubation.  Following incubation, cells were stained 
with anti-CD8 PE-Cy7 and anti-CD3 PerCpCy5.5 mAbs (BD Biosciences) for 
30 min at 4°C and then fixed and permeabilized using Cytofix/Cytoperm™ 
solution (BD Biosciences, San Jose, CA) according to the manufacturer’s 
instructions.  Finally, cells were stained with anti-IFN--PE (BD Biosciences) 
for 30 min on ice, washed, and fixed with 1% formaldehyde before acquisition 
on a FACS Canto flow cytometer.  PBMC were also incubated separately with 5 
μl of HBV-specific HLA-A2 tetramers (ProImmune, Oxford, UK) for 15 min at 
25°C in the dark, washed, followed by staining with anti-CD8 PE-Cy7 and 
acquisition as described above.  IFN-γ ELISPOT assays were performed as 
previously described 30. 
 
Contribution of immune cellular subsets/cytokines in chemokine 
production 
PBMC from 2 healthy donors were cultured with/without HepG2, SNU 368, 
SNU 387 and primary human hepatocytes obtained as described previously 50.  
SNU cell lines were obtained from the Korean Cell Line Research Foundation.  
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100,000 HepG2, SNU 368, SNU 387 cells or 50,000 primary human 
hepatocytes were seeded in each well on a 96-well flat bottom plate.  Primary 
human hepatocytes were seeded on human collagen coated plates.  Plates were 
coated with 2 μg/cm2 of human type I collagen (BD Biosciences, San Jose, CA) 
according to the manufacturer’s protocol.  100,000 PBMC were added the next 
day and cultures were stimulated with LPS (1 µg/ml), CD3/CD28 Dynal Beads 
(Invitrogen, Carlsbad, CA) at a bead to cell ratio of 1:1 or a cocktail of IFN-α 
and CXCL-8 at 4 ng/ml each.  Supernatants from the cultures were collected 
after 24 hours of incubation at 37°C and analyzed for chemokine production. 
The frequency of T, NK cells and monocytes in the PBMC was determined by 
CD3, CD56 and forward and side scattering patterns.  HepG2, SNU 368, SNU 
387 and primary human hepatocytes isolated from a healthy donor were also 
cultured in different combinations of IFN-γ (100 or 1000 IU/ml), IFN-α (400 or 
4000 pg/ml) and TNF-α (10 or 100 ng/ml).  Supernatants after 24 hours of 
culturing were then analyzed for CXCL-9 and CXCL-10 production.   
 
Intra-cellular CXCL-9 and CXCL-10 staining 
SNU 368 cells were incubated with 1000 IU/ml of IFN-γ and 100 ng/ml of 
TNF-α overnight in the presence of BD Golgistop (BD Biosciences, San Jose, 
CA ) (1:12000 dilution) as a protein secretion inhibitor.  The cells were then 
fixed, permeabilized and  stained with anti-CXCL-9 fluorescein and anti-CXCL-
10 PE mAbs (R&D Systems, Minneapolis, MN) for 30 min at room temperature, 
washed, and fixed with 1% formaldehyde before acquisition on a FACS Canto 
flow cytometer. 
 




Statistical significance between subject groups was calculated using non-
parametric Mann-Whitney test.  In both the linear regressions and Mann-
Whitney tests, a P-value equal to or less than 0.05 is considered significant. 
 
 




Longitudinal cytokine/chemokine profile in patients developing HF after 
therapy withdrawal. 
Anti-viral nucleoside analogues are efficient inhibitors of HBV replication (5-6 
Log10 drop in HBV-DNA/ml serum) and normalizer of serum alanine amino-
transferase (ALT) levels, but therapy termination is almost invariably linked 
with an immediate rebound of HBV replication, usually followed by HF 
(characterized by elevated ALT levels -3 times the upper limit of normal) 8-16 
weeks later 100.  We initially studied 5 chronic hepatitis B patients who were 
treated for approximately 2 years with a nucleoside analogue (Remofovir).  The 
immunological and viral events were closely monitored for about 1 year at 
monthly intervals.  The patients studied displayed normal (≤ 70 IU/L) ALT 
levels and HBV-DNA values of 102-103 copies/ml during treatment.  After 
therapy interruption HBV replication rebounded to pre-treatment levels (109-
1010) and after 12-16 weeks, 4 out of 5 patients developed HF. (Figure 1 and 
Table 1).  Serum cytokines (pro-inflammatory and anti-inflammatory), 
chemokines and circulating T, NK and Treg cell populations were studied in 
three distinct phases: during treatment with reduced ALT and low HBV 
replication (~ ≤ 104 HBV-DNA copies/ml) - Green; a phase of viral rebound 
with no change in ALT levels after therapy termination - Blue; and the third 
phase when values of ALT starts to rise with 4 out of 5 patients experiencing HF 
- Red (Figure 1 and Table 1).  
 
Pro-inflammatory cytokines like IL-1β, IL-6 and TNF-α were consistently low 
(<5 pg/ml) or undetectable at all time points in every patient (Figure 2a).  IFN-α 
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serum levels were undetectable both during therapy and during viral rebound 
in all the chronic patients tested and could only be detected in 2 of the 5 chronic 
patients at the time of HF (Figure 2a).  Only CXCL-8, a neutrophil chemo-
attractant capable of suppressing antiviral effect of type I IFN and influencing 
NK cell activation 101, was found to be significantly elevated during the phase of 
viral replication rebound in all HBV patients who developed HF (4 out of 4) (P 
= 0.0341; Figure 2a).  Interestingly, CXCL-8 was not observed only in Pt. 5 
who did not develop HF and have a lower level of viral rebound.  In addition, 
serum CXCL-8 elevation could also be found during flares (2 out of 5 subjects; 
P = 0.0240).  
 
In contrast to what was recently reported in acute HBV patients, serum levels of 
the immune regulatory cytokine IL-10 were consistently low during viral 
rebound after therapy interruption (3.05 pg/ml respectively), while marginally 
higher concentrations (10-15 pg/ml) could be measured only at the time of liver 
injury (P = 0.0044; Figure 2b)..  Linear regression analysis revealed a direct 
correlation between serum IL-10 concentration and ALT levels (R2 = 0.86, P < 
0.0001; Figure 2b). 
 
Longitudinal analysis of the levels of different chemokines able to preferentially 
recruit monocytes (CCL-2 formerly known as MCP-1) and T cells (CXCL-9 and 
CXCL-10, respectively Mig and IP-10) were also sequentially tested.  CCL-2 
serum values were slightly elevated (two time upper level of normal, ≥ 256 
pg/ml) at the time of HF (Supplementary Figure 1); however, a dramatic 
increase in CXCL-9 and CXCL-10 was clearly evident (Figure 3 a and b).  
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Serum CXCL-9 and CXCL-10 levels in chronic HBV patients before and after 
therapy withdrawal were above the levels found in healthy donors (< 100 pg/ml 
in healthy donors) or acute patients after resolution of disease (5 out of 5; data 
not shown), and increased ~5-20 fold at the time of HF (CXCL-9: P < 0.0001, 
CXCL-10: P = 0.0056; Figure 3 a and b).  Both CXCL-9 and CXCL-10 levels 
correlate with ALT (P < 0,0001, Figure 3 a and b) while among all the other 
cytokines tested (IL-1β, IL-6, TNF-α, IFN-α and CXCL-8), only IL-10 values 
was significantly correlated with ALT values.  No correlation was found 
between cytokines/chemokines values and levels of HBV-DNA (data not 
shown).  
 
To confirm the relationship between increased CCL-2, CXCL-9 and CXCL-10 
values and liver injury, chemokine levels were measured cross-sectionally in an 
additional 29 chronic HBV patients (10 patients with spontaneous HF with ALT 
> 300 U/L, 19 chronic HBV patients with consistently normal level of ALT 
with/without nucleoside analogue therapy) and in 5 acute hepatitis B patients at 
the onset of acute hepatitis (ALT > 300).   
 
Elevated levels (~10 times normal levels) of IFN-γ induced chemokines CXCL-
9 and CXCL-10 were detected in HBV patients at the time of HF, but not in 
patients/subjects with normal ALT values (Figure 3c and Supplementary 
Table 1).  In contrast, serum CCL-2 and were only slightly elevated (data not 
shown).  Interestingly, CXCL-9 and CXCL-10 concentrations differed between 
the acute and chronic HBV patient groups.  Chronic patients with HF have 
CXCL-9 and CXCL-10 elevated to similar levels (mean CXCL-9 / CXCL-10 
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concentration: spontaneous flares = 179.4 / 202.4 pg/ml; antiviral withdrawal 
induced = 2543 / 2458 pg/ml), but acute patients have a greater increase in 
CXCL-9 than CXCL-10 (mean CXCL-9 / CXCL-10 concentration: 2631 / 486.9 
pg/ml) (Figure 3c).   
 
Lack of temporal association between NK and virus-specific T cell response 
and hepatic flares.  
Having determined that HF coincided with high levels of IFN-γ inducible 
chemokines CXCL-9 and CXCL-10, we assessed the involvement of HBV-
specific T cells and TRAIL expressing NK cells in triggering HF.  IFN-γ 
secretion following activation of these cellular subsets could trigger the 
production of both chemokines and initiate the cascade of events leading to 
hepatic injury as previously shown 97, 102, 103.  Hence, we serially analyzed 
PBMC from these patients stopping antiviral therapy, before and after 
withdrawal, for the presence of NK cell activation and also quantified HBV-
specific T cell frequencies.    
 
The frequency of total NK cells in the peripheral compartment did not fluctuate 
significantly with respect to the occurrence of HF and only a single patient had 
an increased frequency of total NK cells at the time of HF (Pt. 1: 13%  20% of 
total lymphocytes) (Figure 4a).  In addition, we did not observe an increase in 
the frequency of TRAIL expression on NK (CD56+ and CD56 bright) cells at 
the time of HF, which had been previously demonstrated (Figure 4a) 103.  No 
fluctuations were detected in Pt. 5 who did not develop HF (data not shown).  
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To comprehensively analyze the potential fluctuations of HBV-specific T cell 
frequencies in relation to the development of HF, sequentially collected PBMC 
were stimulated with pools of peptides covering the whole HBV proteome and 
tested for IFN-γ production and/or expression of the de-granulation marker 
CD107a.  Since involvement of PD-1/PD-L1 interaction was suggested to 
inhibit the functional activation of T cells in chronic hepatitis B patients 33, 
experiments were also performed both in the presence or absence of anti-PD-L1 
antibodies.  Despite this extensive methodological approach, ex vivo HBV-
specific T cell responses were undetectable in the 4 patients developing HF at 
every time point tested regardless of the presence/absence of anti-PD-L1 
antibody (Figure 4 b and c; anti-PD-L1 data not shown).  Longitudinal analysis 
with HBV-specific HLA-A2 tetramers in 2 HLA-A2 matched patients in the 
study group confirms the absence of detectable circulating HBV-specific CD8 T 
cells obtained with functional assays (data not shown).   
 
An increased frequency of IFN-γ+/CD107a+ HBV-specific CD8 T cells (1% 
and 4% of total T cells respectively) was only detected 4 weeks post treatment 
withdrawal in the single patient (Pt. 5) who didn’t developed HF and maintained 
a lower replication of HBV (< 106 HBV-DNA copies/ml) (Figure 4b).  In this 
patient, HBV-specific CD8 T cells could be detected at different time points (18 
weeks before and 4, 8, and 12 weeks after therapy interruption) consistent with 
the hypothesis that circulating HBV-specific CD8 T cells correlate with viral 
control and not with liver damage 31.  
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To further investigate HBV-specific T cell responses in patients that develop 
spontaneous HF, we analyzed HBV-specific T cell responses in 5 patients at the 
time of HF (ALT > 700) using the ELISPOT assay and stimulating T cells with 
HBV peptides covering the viral proteome.  Similar to the results obtained in 
patients after therapy withdrawal, HBV-specific T cell responses were not 
detected in any of the patients at the time of HF (data not shown).  
 
Treg cells and T cell response 
Since Treg cells (CD4+ FoxP3+) were suggested to modulate HBV-specific T 
cell responses in chronic patients 44, 45, 104, the frequency of this population was 
also analyzed.  Treg cells were analyzed using classical CD4, CD25 and FoxP3 
markers and also with CD39, a surface marker representing the ectodomain of 
ATPase enzyme that mediates the depletion of ATP (recently described 
regulatory mechanism) and was shown to be expressed on Treg cells 105.  There 
was no increase in Treg cells, either CD25+ FoxP3+ CD4 cells or CD39+ CD4 
cells, at all the time points tested, suggesting that these cells may not play any 
role in inhibiting HBV-specific T cell responses in vivo (Figure 4d). 
 
In vitro characterization of CXCL-9 and CXCL-10 expression. 
The disparity between CXCL-9/10 values present in the serum of acute versus 
chronic patients at the time of liver injury suggested that these chemokines 
could be stimulated by different mechanisms.  In addition to IFN-γ, recent work 
has demonstrated a requirement of innate cytokines like IFN-α and TNF-α for 
their production 106.  Thus, to better characterize the requirement for their 
hepatic expression, CXCL-9 and CXCL-10 secretion by three different 
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hepatocellular carcinoma cell lines (HepG2, SNU 368 and SNU 387) and 
primary human hepatocytes were stimulated with IFN-γ, TNF-α and IFN-α 
alone or in combination for 24 hours before the supernatants were collected and 
analyzed.   
 
Since HepG2 cells were able to produce CXCL-10, but not CXCL-9 under any 
conditions (Supplementary Figure 2), this line was excluded from further 
analysis.  As expected, IFN-γ was sufficient to induce production of both 
CXCL-9 and CXCL-10 chemokines in normal hepatocytes and in the HCC lines 
(Figure 5a).  Interestingly, CXCL-10 production can be consistently triggered 
by IFN-α and TNF-α alone or in combination (Figure 5a).  Of note, co-
stimulation with IFN-α and TNF-α induces levels of CXCL-10 secretions 
comparable to that obtained by IFN-γ.  In addition, TNF-α substantially boosts 
CXCL-9 production induced by IFN-γ in all HCC lines and in normal 
hepatocytes, supporting the synergistic role of TNF-α in CXCL-9 production 
showed in mice 106 (Figure 5a). 
 
We then mimicked activation of different cellular populations present in the 
inflammatory hepatic infiltrate (T cells, NK, Macrophages) and examined how 
this differentially regulate CXCL-9 or CXCL-10 production.  PMBC were 
activated with different cell specific stimuli (T cells: anti-CD3/anti-CD28 beads; 
NK cells: IFN-α + IL-8; monocytes: LPS) and co-cultured with normal 
hepatocytes and HCC lines for 24hours.  Figure 5b shows that while activated T 
cells trigger the expression of both CXCL-9 and CXCL-10 (skewed towards 
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CXCL-9), macrophages and NK cell activation triggers, at least in vitro, 
mainly CXCL-10 production. 
 




Although animal models have described in detail the mechanisms responsible 
for liver inflammation, namely the intrahepatic recruitment of inflammatory 
cells (monocytes, T cells) orchestrated by chemokines (CXCL-9/10) 97, and 
requiring the contribution of granulocytes 98, 107, we still lack the demonstration 
that these events are taking place in humans.  Furthermore, animal models 
require some artificial manipulation (i.e. adoptive transfer of HBV-specific CTL, 
induced activation of liver resident NK-T cells through α-galactoceramide or 
hydrodynamic transfection of HBV genes into the liver) to trigger liver damage 
108, 109.  For this reason, and the difficulties of obtaining frequent sequential 
samplings in patients before the triggering of the HF, the immunological and 
virological events responsible to set off HF in chronic hepatitis B patients 
remain arguments of controversy.  Here, the follow-up (10-12 months-4 weeks 
intervals) of a restricted group of chronic hepatitis B patients that voluntarily 
ceased anti-viral treatment (n=5) permitted a precise sequential analysis of 
virological and immunological events before and during HF. 
 
The first observation was that the rebound of HBV replication following therapy 
withdrawal did not trigger any immunological events related to innate immune 
activation.  Despite the fact that HBV replication increased by about 5-6 log in 
the 10-12 weeks before HF, serum values of pro-inflammatory cytokines (IL-1, 
TNF-α, IL-6 and IFN-α) were consistently normal (< 15 pg/ml).  The absence of 
a classical pro-inflammatory cytokine pattern 110 and the extended time period 
before the triggering of HF (12 weeks on average in all patients) are similar to 
the kinetics of acute HBV infection which is characterized by a long incubation 
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time (8-12 weeks) before the onset of liver injury 111 and underlies the 
peculiarity of HBV infection.  Hepatic infection with other viruses like HCV, 
MCMV and adenovirus immediately trigger activation of IFN-α genes and a 
cascade of events characterized by instant high production of CCL-2, CCL-3, 
CXCL-9 and CXCL-10 42, 112, 113.  Although our data was derived from the 
reactivation of HBV replication (from 102-3 to 109- 1010) and not from primary 
infection, the almost complete absence of signs of immune reactivation during 
the rebound of HBV replication is in agreement with the suggestion that HBV 
might escape intracellular innate immune recognition mechanisms (i.e. TLR3, 7 
and 9) and early NK cell recognition 22.  Another possible interpretation of this 
pervasive immunological tolerance during HBV rebound is the presence of 
strong immune-regulatory mechanisms like IL-10 and Treg cells.  However such 
a scenario was not supported by our findings; neither Treg nor IL-10 levels were 
elevated before HF.  On the contrary, an increase in serum IL-10 was only 
observed during liver injury, probably as a homeostatic compensatory 
mechanism against inflammation.  In this respect, our data obtained in 
chronically infected patients do not confirm recent results obtained in acute 
hepatitis B patients that have suggested increased HBV replication could trigger 
IL-10 production 114.  
 
A notable exception in the profile of immunological tolerance during the initial 
phase of HBV rebound was the detection of high values of CXCL-8 (IL-8) in 4 
out of 5 chronic HBV patients.  CXCL-8 is a chemokine able to recruit 
granulocytes, NK cells and T cells to the inflammatory site 115 and might also 
interfere with the anti-viral effect of IFN-α 101.  In addition, it has been shown to 
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be elevated prior to HF where it was proposed to synergize with IFN-α to 
activate NK cells 103.  Here, we confirm CXCL-8 elevation prior to HF; however, 
the association of high CXCL-8 in the presence of normal ALT values is 
difficult to reconcile with its proposed role in liver injury (directly or through 
NK cell activation).  At the moment, our data are insufficient to decipher the 
effect of CXCL-8 during HF.  However, it is very likely that this chemokine has 
a role during hepatic infection because we have also detected high CXCL-8 
values during acute HBV, but not during other acute viral infections (dengue, 
influenza, adenovirus) (A. Bertoletti, unpublished data).  
 
The second important observation is the clear involvement of CXCL-9/10 in HF. 
High serum levels of CXCL-9 and CXCL-10 were temporally associated with 
HF in patients studied longitudinally and were also found in chronic hepatitis B 
patients with high levels of ALT.  In addition, other chemokines like CCL-2 
(Supplementary Figure 1) and CCL-3 (data not shown) were only minimally 
elevated or undetectable.  Their significance in relation to macrophage 
involvement in HF could require further investigation.  CXCL-10 and CXCL-9 
are potent chemo-attractants of activated T cells 116 and have been shown in 
several animal models to recruit antigen-specific and inflammatory T cells to the 
liver 97, 106.  Thus, these data are not only in agreement with the major 
involvement of T cells in the inflammatory infiltrate present in the viral hepatitis, 
but it also extends the previous observation of increased CXCL-9/10 levels in 
HCV-related hepatitis 117, 118 and in HIV-HBV co-infected patients 119 to 
hepatitis B patients.  In addition to its involvement in T cell recruitment, CXCL-
10 has been shown to present hepato-protective properties, inhibiting liver 
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damage and promoting liver regeneration 120.  It is thus possible that CXCL-
10, in addition to IL-10 that was slightly elevated at the time of HF, might play a 
role not only in inducing inflammation but also in preserving liver viability.   
 
Despite the involvement of CXCL-9/10 in HF, the observed temporal 
correlation with HF does not clarify the cause of the triggering.  We were able to 
show in vitro that IFN-γ is necessary for both CXCL-9/10 production by 
hepatocytes, which was mimicked more closely by activation of T cells and not 
by monocytes or NK activation, suggesting a direct involvement of T cells on 
HF.  Using a peptide library covering the entire proteome of HBV, anti-PDL1 
antibodies and the highly sensitive ELISPOT assay, we were unable to detect 
HBV-specific T cells in the periphery during the occurrence of HF.  Thus, we 
could not correlate an increase of circulatory HBV-specific T cell response (as 
well as circulatory activated NK-cells) with the presence of HF.  On the contrary, 
an increased HBV-specific T cell response was detectable in the only patient 
that maintained a lower level of HBV-replication and didn’t develop HF 
following antiviral withdrawal, in line with the correlation of HBV-specific T 
cell response with viral control more than with liver injury.   
 
A possible reconciling scenario is that the pool of HBV-specific CD8 T cells, 
preferentially retained in the liver by the expression of CXCR3 121, will not 
necessary increase in numbers but only differentially respond to different 
quantity of HBV antigens expressed by hepatocytes.50.  While low quantities of 
HBV antigens activates only CTL de-granulation (and thus only lead to the 
possible selective lysis of few hepatocytes), higher doses of antigens induce 
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IFN-γ and TNF-α production, cytokines that we have seen are clearly able to 
trigger CXCL-9/10 expression in hepatocytes.  A progressive increase of HBV-
DNA values was observed in all the subjects that develop flares, which might 
indicate a progressive increase of HBV antigens before the triggering of HF in 
line with the data of Maruyma et al 94.  Therefore, we favor the idea that an 
increment of HBV antigens presented by infected hepatocytes or by hepatic 
antigen presenting cells might modulate the intra-hepatic HBV-CD8 T cell 
function and set off HF.  Even though circumstantial evidences support such a 
scenario, it is not possible to exclude the possibility that changes in the HBV 
antigen levels can trigger HF alone or in associations with cytokines or other 
components of the immune system (like NK or macrophages). 
 
In this regard, the differential balance between CXCL-9 and CXCL-10 values in 
acute versus chronic hepatitis B patients during liver injury is intriguing.  We 
show here that the two chemokines are triggered differently.  Large in vitro 
CXCL-9 production is mainly triggered following T cell activation, requires 
IFN-γ and can be enhanced through the synergistic effect of TNF-α.  In contrast, 
CXCL-10 production can be triggered in the absence of IFN-γ.  This in vitro 
result is somewhat in line with our ex vivo observation.  Dysfunctional T cells 
are a hallmark of chronic HBV infection while patients who resolve the 
infection are characterized with poly-functional T cell response 30, 33.  The 
presence of functional T cells producing IFN-γ and TNF-α in acutely infected 
patients could represent the source of signals necessary for CXCL-9 secretion 
which leads to the observed biased elevation of CXCL-9 versus CXCL-10.  In 
contrast, dysfunctional T cells (and perhaps the involvement of activated 
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monocytes and NK cells) present in chronic patients which is inferior in IFN-γ 
production 33 might result in the expression of identical levels of CXCL-9/10 
observed in chronic patients.  
 
In conclusion, our analysis offers a comprehensive and detailed scenario of the 
kinetics of virological and immunological events associated with HF.  We 
demonstrate that both HBV replication rebound and HF were not associated 
with a recovery of peripheral HBV-specific T cell immunity and confirm that 
CXCL-9 and CXCL-10 are major mediators of liver inflammation.  Also, the 
existence of differing mechanisms that govern CXCL-9 and CXCL-10 secretion 
could in turn mediate distinct pathogenic mechanisms of liver injury in acute 
and chronic HBV patients. 
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Table 1.  Longitudinal clinical data of patients who withdrew from Remofovir 
treatment.  Time points are denoted as weeks relative to therapy withdrawal.  Green 
regions refer to the phase where the patient is undergoing therapy.  Blue regions refer to the 
viral rebound phase without HF after therapy withdrawal.  Red regions refer to the HF phase 
characterized by elevated ALT levels. 
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Figure 1.  Temporal dissociation of viral rebound and hepatic injury.  Serum HBV 
DNA (●) and ALT levels (○) during treatment, as well as after therapy withdrawal are 
indicated.  Time points are denoted as weeks relative to therapy withdrawal.  The lag time 
for hepatic injury (elevated ALT levels) to occur is indicated by the red line.  Some of the 
patients were placed on Adefovir (ADV) treatment following Remofovir termination as 
indicated on each graph. 
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Figure 2.  Pro-inflammatory and anti-inflammatory cytokine profile of the distinct 
disease phases.  Serum cytokine concentrations at the different time points were quantified 
by the cytometric bead array system and the results were grouped into the corresponding 
disease phases.  Each dot represents a single time point of the longitudinal measurements 
from 5 chronic patients at a total of 41 time points.  The mean cytokine concentrations at 
each disease phase are indicated.  Differences between groups were tested using non-
parametric Mann-Whitney test and only P-values below 0.05 are shown.  A) Pro-
inflammatory cytokine profile.  B) Anti-inflammatory IL-10 profile (left panel).  A 
representative longitudinal profile of serum IL-10 concentration is shown (middle panel; 
blue bars).  Serum HBV DNA (●) and ALT levels (○) during treatment, as well as after 
therapy withdrawal are indicated.  Linear regression analysis (right panel) of serum IL-10 
concentrations against ALT levels is depicted.  1 data point is outside the scale used but is 
included in the analysis.  The 95% confidence interval bands are indicated as dotted lines. 
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Figure 3.  Strong correlation of serum CXCL-9 and CXCL-10 concentrations with 
hepatic injury.  Serum A) CXCL-9 and B) CXCL-10 concentrations at the different time 
points were quantified by the cytometric bead array system and the results are presented 
similar to Figure 2b.  C) Serum CXCL-9 and CXCL-10 concentrations measured in various 
patient groups with elevated (acute, spontaneous flares and antiviral withdrawal induced 
flares) or normal (chronic patients without HF and healthy subjects) ALT is shown.  The 
mean cytokine concentrations at each disease phase are indicated. 
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Figure 4.  Quantification of HBV-specific T cells, NK cells and Treg.  A) Frequency of 
total NK cells, TRAIL+ activated NK cells and TRAIL+ CD56 bright NK cells were 
quantified before and during HF by flow cytometry.  Each dot represents a single time point 
of the measurements from 5 chronic patients at a total of 18 time points.  The mean 
frequency of each cell population during each disease phase is indicated.  B) Frequency of 
HBV-specific T cells were quantified by stimulating PBMC with a peptide library covering 
the entire proteome of HBV genotype B and staining for IFN-γ (yellow bars) and CD107a 
(orange bars).  3 representative longitudinal profiles are shown.  Serum HBV DNA (●) and 
ALT levels (○) during treatment, as well as after therapy withdrawal are indicated.  C) 
Mean frequency of HBV-specific T cells (IFN-γ+ or CD107a+ T cells after stimulation with 
peptides) in patients with HF after antiviral withdrawal and in a patient who did not develop 
flares.  D) Frequency of CD39+ CD4+ and FoxP3+ CD25+ CD4+ Tregs were quantified 
before and during HF by flow cytometry.  Each dot represents a single time point of the 
measurements from 3 chronic patients at a total of 19 time points.  The mean frequency of 
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Figure 5.  Contribution of cellular and secreted factors in CXCL-9 and CXCL-10 
production by human hepatocytes.  A) Primary human hepatocytes and HCC cell lines 
(SNU 368 and SNU 387) were cultured in the presence of various combinations of IFN-γ, 
IFN-α and TNF-α.  The concentration of CXCL-9 and CXCL-10 in the supernatants was 
quantified after 24 hours.  Dark and light bars represent the mean concentration of CXCL-9 
and CXCL-10 from 2 experiments, with the exception of the primary hepatocytes where 
limited liver material forbid the repetition.  A representative dot plot of intra-cellular 
CXCL-9 and CXCL-10 staining of SNU 368 after IFN-γ and TNF-α stimulation is shown.  
The dot plots were gated for the SNU 368 cells by the forward and side scatter patterns.  
The frequency of events in the respective quadrants are shown.  B) Primary human 
hepatocytes and HCC cell lines were also cultured with/without PBMCs from a healthy 
donor and stimulated with CD3/CD28, lipopolysaccharide and a cocktail of IFN-α and IL-8 
to stimulate T cells, monocytes and NK cells respectively.  The presence (+) and absence (-) 
of each cell types in the cultures are shown accordingly.  Concentrations of each 
chemokines were normalized to the number of stimulators (T cells, monocytes and NK 


















Concentration (pg/ml) 2543 179.4
Mean CXCL-10 
Concentration (pg/ml) 2458 202.4
Supplementary Table 1.  Comparison of serum ALT, CXCL-9 and CXCL-10 levels in 
patients with spontaneously occurring and antiviral withdrawal induced hepatic 
flares.  The mean values of each parameter in the respective patient groups are shown. 
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Supplementary Figure 1.  Slight elevation of serum CCL-2 during hepatic flares.  Serum 
cytokine concentrations at the different time points were quantified by the cytometric bead 
array system and the results were grouped into the corresponding disease phases.  Each dot 
represents a single time point of the longitudinal measurements from 5 chronic patients at a 
total of 41 time points.  The mean cytokine concentrations at each disease phase are 
indicated.  Differences between groups were tested using non-parametric Mann-Whitney 
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Supplementary Figure 2.  CXCL-9 and CXCL-10 profile of in vitro cytokine 
stimulated HepG2 cells.  HepG2 cells were cultured in the presence of various 
combinations of IFN-γ, IFN-α and TNF-α.  The concentration of CXCL-9 and CXCL-10 in 
the supernatants was quantified after 24 hours.  Dark and light bars represent the mean 













The immunology of HBV infection is a complex issue with many still 
unanswered aspects that require extensive investigation.  This thesis fills up 
these gaps in the understanding of the virus-specific T cell responses and 
pathogenesis by providing; 1) the first comparative study between two HBV 
infected patient populations; and 2) clinical evidence of the pathogenetic 
mechanisms of HBV-associated liver injury. 
 
We showed that the dichotomy of HBV-specific T cell responses is a universal 
phenomenon observed in HBV patients infected with different HBV genotypes 
and of different genetic backgrounds.  On the other hand, the repertoire of the T 
cell response appears to be altered by variations in both the viral proteome 
sequence and the HLA haplotypes, suggesting that the analysis of virus-specific 
T cell responses have to be tailored to the specific patient population.  These 
findings clearly have important implications for the protective role of the 
immune response against HBV.   
 
However, though it is intuitive to consider the HBV immune response as a 
solely protective mechanism against the virus, the non-cytopathic nature of 
HBV and the occurrence of liver inflammation during the natural history of 
HBV infection automatically places the HBV immune response at the other end 
of the spectrum where it could also mediate hepatic damage.  Delineating the 
mechanisms of liver damage during HBV infection then becomes a topic of 
interest.  Using a cohort of patients where hepatic injury and viral replication 




is an unlikely factor responsible for the direct damage of the liver, and that 
hepatic injury during HBV reactivation is likely to be mediated by the hepatic 
secretion of chemokines CXCL-9 and CXCL-10.   
 
Common to both studies, these analyses were primarily focused on the 
peripheral compartment.  Even though such work can provide very important 
insights into the immunology of HBV, the hepatotropism of the virus could 
result in distinct immunological characteristics specific only to the liver and not 
in the periphery.  Future studies would have to attempt to move the analysis into 
the physiologically relevant liver compartment, a task both daunting and 
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